NAV
Explore a selection of essential drug information below, or:
Unlock enhanced features & extensive drug insights. Create a free account.
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Nitroglycerin

Explore a selection of our essential drug information below, or:

CREATE FREE ACCOUNT
Full Drug Profiles
Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.
SUBSCRIBERECOMMENDED FOR PHARMA
Data Packages
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Identification

Summary

Nitroglycerin is a nitrate vasodilator used to treat or prevent angina, heart failure, hypertension, and anal fissures.

Brand Names
Gonitro, Minitran, Mylan-nitro, Nitro-bid, Nitro-dur, Nitroject, Nitrolingual, Nitromist, Nitrostat, Rectiv, Trinipatch
Generic Name
Nitroglycerin
DrugBank Accession Number
DB00727
Background

Nitroglycerin, also known as glyceryl trinitrate,2 is an organic nitrate and a vasodilating agent 17 that was first discovered in 1847.9 Originally used to dynamite, its antianginal effects were identified in the late 1860s after it produced headaches in factory workers while workers with angina pectoris or heart failure experienced relief from chest pain.1,3 Its use as a treatment for angina dates back to 1879 and is still used to treat and prevent angina.10 Nitroglycerin causes vasodilation in both arteries and veins.3

Nitroglycerin is used in a variety of different conditions, including angina pectoris due to coronary artery disease,12,14,17,15 peri-operative hypertension, congestive heart failure,11 and chronic anal fissure.16 It is also used to induce intraoperative hypotension.11

Type
Small Molecule
Groups
Approved, Investigational
Structure
3D
Similar Structures
Weight
Average: 227.0865
Monoisotopic: 227.002578773
Chemical Formula
C3H5N3O9
Synonyms
  • 1,2,3-propanetrioltrinitrate
  • 1,2,3-propanetriyl nitrate
  • Glycerin trinitrate
  • Glycerol trinitrate
  • Glycerol, nitric acid triester
  • Glyceroli trinitratis
  • Glyceroltrinitrat
  • Glyceryl trinitrate
  • NG
  • Nitroglicerina
  • Nitroglycerin
  • Nitroglycerine
  • Nitroglycerol
  • Nitromed
  • Propane-1,2,3-triyl trinitrate
  • Trinitrine
  • Trinitroglycerin
  • Trinitroglycerol
External IDs
  • DR 66
  • IMX-150
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Sublingual nitroglycerin is indicated for the acute relief of an attack or acute prophylaxis of angina pectoris due to coronary artery disease.12,17,15 Transdermal nitroglycerin is indicated for the prevention of angina pectoris due to coronary artery disease.14

Intravenous nitroglycerin is indicated for the treatment of peri-operative hypertension; for control of congestive heart failure in the setting of acute myocardial infarction; for treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and beta (β)-blockers; and for induction of intraoperative hypotension.11

Topical nitroglycerin ointment is used to treat moderate to severe pain associated with chronic anal fissure.16

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Management ofAngina attacks••••••••••••
Management ofAngina pectoris•••••••••••••••••••••• •••••••• •• •••••••••• •••••••••••••• •••••••••••• •••••••• •• •••••••••••••
Prevention ofAngina pectoris••••••••••••
Prophylaxis ofAngina pectoris••••••••••••
Used in combination to manageAngina pectorisCombination Product in combination with: D-glucose (DB01914)••••••••••••••••••••
Used in combination to preventAngina pectorisCombination Product in combination with: D-glucose (DB01914)••••••••••••••••••••
Management ofCongestive heart failure (chf)••••••••••••••••••• •• •••••••••• ••••••••••
Management ofPerioperative hypertension••••••••••••
Management ofModerate to severe pain••••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Nitroglycerin causes the relaxation of vascular smooth muscles, causing arteriolar and venous dilatation.17 It increases blood flow to the myocardium and reduces cardiac preload and afterload, decreasing myocardial wall stress and ameliorating anginal symptoms.3,10,12 Nitroglycerin also reduces coronary artery spasm, decreasing systemic vascular resistance as well as systolic and diastolic blood pressure.17

Like other organic nitrates, repeated and prolonged administration of nitroglycerin can lead to the development of tolerance or desensitization of vascular smooth muscle to further nitroglycerin-induced vasorelaxation. This loss of efficacy may be associated with the inhibition of mitochondrial aldehyde dehydrogenase, which is an important enzyme involved in the bioactivation of nitroglycerin.1,2,3 Nitroglycerin tolerance may be accompanied by pro-oxidant effects, endothelial dysfunction, and increased sensitivity to vasoconstrictors.3

Mechanism of action

Nitroglycerin is converted by mitochondrial aldehyde dehydrogenase in smooth muscle cells to nitric oxide (NO), a potent vasodilator. NO activates the enzyme guanylate cyclase, which converts guanosine triphosphate (GTP) to cyclic guanosine 3',5'-monophosphate (cGMP) in vascular smooth muscle and other tissues.1,2,10 cGMP is an endogenous vasodilator of vascular smooth muscle:3 it causes protein kinase-dependent phosphorylation and activates downstream cascades that promote relaxation and increased blood flow in veins, arteries and cardiac tissue.3,10 An in vitro study using mouse aorta suggests that nitric oxide, an active metabolite of nitroglycerin, targets the natriuretic peptide receptors.7

TargetActionsOrganism
UAtrial natriuretic peptide receptor 1
agonist
Humans
Absorption

Nitroglycerin is rapidly absorbed and is often used in emergency situations for this reason.10 After a sublingual dose of 0.5 mg of nitroglycerin in patients with ischemic heart disease, the peak concentration (Cmax) was 2.56 ng/mL and the mean Tmax was 4.4 minutes.4

The Cmax following a 0.6mg dose of sublingual nitroglycerin was 2.1 ng/mL and the Tmax was 7.2 minutes.17 The absolute bioavailability following sublingual administration was about 40%. The bioavailability of nitroglycerin depends on several factors, such as mucosal metabolism and hydration status, which both affect the absorption of sublingual drugs.17

Volume of distribution

The volume of distribution of nitroglycerin is 3 L/kg.11

Protein binding

After a sublingual dose of nitroglycerin, at concentrations in the plasma ranging from 50 to 500 ng/mL, plasma protein binding of nitroglycerin is about 60%. The plasma protein binding of the metabolites 1,2-dinitroglycerin is 60% and that of 1,3-dinitroglycerin is 30%.17

Metabolism

Mitochondrial aldehyde dehydrogenase 2 (ALDH2) promotes the bioactivation of nitroglycerin. Nitroglycerin is metabolized to nitrite; 1,2-glyceryl dinitrate; and 1,3 glyceryl dinitrate.1,8,11 Nitrite is further metabolized to nitric oxide. 1,2- and 1,3-dinitroglycerols are less biologically active than nitroglycerin but they have longer half-lives, which explains some prolonged effects of nitrates. Both dinitrates are finally metabolized to glycerol, carbon dioxide, and mononitrates that do not have vasodilatory actions.6,11

Nitroglycerin can also chemically react with a thiol to generate an intermediate S-nitrosothiol, which resulted in further production of nitric oxide.1,3,8

Hover over products below to view reaction partners

Route of elimination

Metabolism is the main route by which nitroglycerin is eliminated from the body.17

Half-life

Following intravenous administration, the plasma half-life is about three minutes.5,11 The estimated plasma half-life following sublingual administration is approximately six minutes.4 The elimination half-lives of metabolites 1,2-dinitroglycerin and 1,3-dinitroglycerin range between 32 to 26 minutes.17

Clearance

The estimated clearance following intravenous administration is 1 L/kg/min.11 The apparent clearance after a sublingual dose was 21.9 L/min in a pharmacokinetic study of patients with ischemic heart disease and angina.4

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

The oral LD50 of nitroglycerin in rats is 105 mg/kg and the LD50 of the intravenous form in rats is 23.2 mg/kg.13

Nitrate overdosage can result in following conditions: severe hypotension, persistent throbbing headache, vertigo, palpitation, visual disturbance, flushing and perspiring skin (later becoming cold and cyanotic), nausea and vomiting (possibly with colic and even bloody diarrhea), syncope (especially in the upright posture), methemoglobinemia with cyanosis and anorexia, initial hyperpnea, dyspnea and slow breathing, slow pulse (dicrotic and intermittent), heart block, increased intracranial pressure with cerebral symptoms of confusion and moderate fever, paralysis and coma followed by clonic convulsions, and possibly death due to circulatory collapse.17

Methemoglobinemia can rarely occur at conventional doses of organic nitrates. This condition is dose-related and it can be even more pronounced in patients with genetic abnormalities of hemoglobin that favor methemoglobin formation. Methemoglobinemia can be managed with the administration of methylene blue unless the patient has a known G-6-PD deficiency.17

There are no known antidotes to an overdose of nitroglycerin, and it is not known whether its metabolites can be removed from the circulation.17,11 Hypotension associated with nitroglycerin overdose can be managed with different symptomatic and supportive measures, including the elevation of the lower limbs, administration of intravenous saline or other fluids to maintain central fluid volume, and administration of oxygen and artificial ventilation. Gastric lavage may be used in case of ingestion of excess nitroglycerin.17

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbaloparatideThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Abaloparatide.
AcebutololNitroglycerin may increase the hypotensive activities of Acebutolol.
AceclofenacThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Aceclofenac.
AcemetacinThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Acemetacin.
AcetaminophenThe risk or severity of methemoglobinemia can be increased when Acetaminophen is combined with Nitroglycerin.
Acetylsalicylic acidThe serum concentration of Nitroglycerin can be increased when it is combined with Acetylsalicylic acid.
AlbuterolSalbutamol may decrease the antihypertensive activities of Nitroglycerin.
AlclofenacThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Alclofenac.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nitroglycerin.
AlfentanilAlfentanil may decrease the antihypertensive activities of Nitroglycerin.
AlfuzosinAlfuzosin may increase the hypotensive activities of Nitroglycerin.
AliskirenNitroglycerin may increase the hypotensive activities of Aliskiren.
AlmotriptanAlmotriptan may decrease the antihypertensive activities of Nitroglycerin.
AlteplaseThe serum concentration of Alteplase can be decreased when it is combined with Nitroglycerin.
AmbrisentanNitroglycerin may increase the hypotensive activities of Ambrisentan.
AmifostineNitroglycerin may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Nitroglycerin.
AminophenazoneThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Aminophenazone.
Aminosalicylic acidThe risk or severity of methemoglobinemia can be increased when Aminosalicylic acid is combined with Nitroglycerin.
AmiodaroneAmiodarone may increase the vasodilatory activities of Nitroglycerin.
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Nitroglycerin.
AmitriptylinoxideAmitriptylinoxide may decrease the antihypertensive activities of Nitroglycerin.
AmlodipineAmlodipine may increase the vasodilatory activities of Nitroglycerin.
AmobarbitalAmobarbital may increase the hypotensive activities of Nitroglycerin.
AmoxapineAmoxapine may decrease the antihypertensive activities of Nitroglycerin.
AmphetamineAmphetamine may decrease the antihypertensive activities of Nitroglycerin.
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nitroglycerin.
Amyl NitriteThe risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Amyl Nitrite.
AntipyrineThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Antipyrine.
AntrafenineThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Antrafenine.
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Nitroglycerin.
AprocitentanNitroglycerin may increase the hypotensive activities of Aprocitentan.
ArbutamineArbutamine may decrease the antihypertensive activities of Nitroglycerin.
ArformoterolArformoterol may decrease the antihypertensive activities of Nitroglycerin.
AripiprazoleThe risk or severity of hypotension can be increased when Aripiprazole is combined with Nitroglycerin.
Aripiprazole lauroxilThe risk or severity of hypotension can be increased when Aripiprazole lauroxil is combined with Nitroglycerin.
Arsenic trioxideThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Arsenic trioxide.
ArticaineThe risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Articaine.
AsenapineAsenapine may decrease the antihypertensive activities of Nitroglycerin.
AtenololAtenolol may increase the hypotensive activities of Nitroglycerin.
AtomoxetineAtomoxetine may decrease the antihypertensive activities of Nitroglycerin.
AtropineAtropine may decrease the antihypertensive activities of Nitroglycerin.
AvanafilAvanafil may increase the hypotensive activities of Nitroglycerin.
Azilsartan medoxomilNitroglycerin may increase the hypotensive activities of Azilsartan medoxomil.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Nitroglycerin.
BalsalazideThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Balsalazide.
BenazeprilBenazepril may increase the hypotensive activities of Nitroglycerin.
BendroflumethiazideThe therapeutic efficacy of Nitroglycerin can be increased when used in combination with Bendroflumethiazide.
BenorilateThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Benorilate.
BenoxaprofenThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Benoxaprofen.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Benzocaine.
BenzphetamineBenzphetamine may decrease the antihypertensive activities of Nitroglycerin.
BenzthiazideThe therapeutic efficacy of Nitroglycerin can be increased when used in combination with Benzthiazide.
BenzydamineThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Benzydamine.
BepridilBepridil may increase the vasodilatory activities of Nitroglycerin.
BetaxololBetaxolol may increase the hypotensive activities of Nitroglycerin.
BethanidineBethanidine may decrease the antihypertensive activities of Nitroglycerin.
BimatoprostNitroglycerin may increase the hypotensive activities of Bimatoprost.
BisoprololBisoprolol may increase the hypotensive activities of Nitroglycerin.
BosentanBosentan may increase the hypotensive activities of Nitroglycerin.
BretyliumNitroglycerin may increase the hypotensive activities of Bretylium.
BrexpiprazoleBrexpiprazole may decrease the antihypertensive activities of Nitroglycerin.
BrimonidineBrimonidine may increase the antihypertensive activities of Nitroglycerin.
BromocriptineThe bioavailability of Bromocriptine can be increased when combined with Nitroglycerin.
BumadizoneThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Bumadizone.
BumetanideThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Bumetanide.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Bupivacaine is combined with Nitroglycerin.
BuspironeBuspirone may decrease the antihypertensive activities of Nitroglycerin.
ButabarbitalButabarbital may increase the hypotensive activities of Nitroglycerin.
ButalbitalButalbital may increase the hypotensive activities of Nitroglycerin.
ButriptylineButriptyline may decrease the antihypertensive activities of Nitroglycerin.
CabergolineThe bioavailability of Cabergoline can be increased when combined with Nitroglycerin.
CanagliflozinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Canagliflozin.
Candesartan cilexetilNitroglycerin may increase the hypotensive activities of Candesartan cilexetil.
CannabidiolCannabidiol may decrease the antihypertensive activities of Nitroglycerin.
CaptoprilNitroglycerin may increase the hypotensive activities of Captopril.
CarbetocinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Carbetocin.
CarbidopaThe risk or severity of hypotension can be increased when Carbidopa is combined with Nitroglycerin.
CariprazineCariprazine may decrease the antihypertensive activities of Nitroglycerin.
CarprofenThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Nitroglycerin.
CarvedilolCarvedilol may increase the vasodilatory activities of Nitroglycerin.
CelecoxibThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Celecoxib.
CeliprololNitroglycerin may increase the hypotensive activities of Celiprolol.
ChloroquineThe risk or severity of methemoglobinemia can be increased when Chloroquine is combined with Nitroglycerin.
ChlorothiazideThe therapeutic efficacy of Nitroglycerin can be increased when used in combination with Chlorothiazide.
ChlorpromazineChlorpromazine may decrease the antihypertensive activities of Nitroglycerin.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Nitroglycerin.
Choline magnesium trisalicylateThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Choline magnesium trisalicylate.
CilazaprilNitroglycerin may increase the hypotensive activities of Cilazapril.
CinnarizineCinnarizine may increase the vasodilatory activities of Nitroglycerin.
ClenbuterolClenbuterol may decrease the antihypertensive activities of Nitroglycerin.
ClevidipineClevidipine may increase the vasodilatory activities of Nitroglycerin.
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Nitroglycerin.
ClomipramineClomipramine may decrease the antihypertensive activities of Nitroglycerin.
ClonidineThe risk or severity of hypotension can be increased when Clonidine is combined with Nitroglycerin.
ClozapineClozapine may decrease the antihypertensive activities of Nitroglycerin.
ConivaptanThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Conivaptan.
CryptenamineNitroglycerin may increase the hypotensive activities of Cryptenamine.
CyclandelateCyclandelate may increase the vasodilatory activities of Nitroglycerin.
CyclopenthiazideThe therapeutic efficacy of Nitroglycerin can be increased when used in combination with Cyclopenthiazide.
CyclophosphamideThe risk or severity of methemoglobinemia can be increased when Cyclophosphamide is combined with Nitroglycerin.
CyclosporineCyclosporine may decrease the antihypertensive activities of Nitroglycerin.
CyclothiazideThe therapeutic efficacy of Nitroglycerin can be increased when used in combination with Cyclothiazide.
DapagliflozinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Dapagliflozin.
DapsoneThe risk or severity of methemoglobinemia can be increased when Dapsone is combined with Nitroglycerin.
DasiglucagonNitroglycerin may increase the hypotensive activities of Dasiglucagon.
DebrisoquineNitroglycerin may increase the hypotensive activities of Debrisoquine.
DeserpidineNitroglycerin may increase the hypotensive activities of Deserpidine.
DesfluraneDesflurane may decrease the antihypertensive activities of Nitroglycerin.
DesipramineDesipramine may decrease the antihypertensive activities of Nitroglycerin.
DesmopressinDesmopressin may decrease the antihypertensive activities of Nitroglycerin.
DexibuprofenThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Dexibuprofen.
DexketoprofenThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Dexketoprofen.
DexmedetomidineDexmedetomidine may decrease the antihypertensive activities of Nitroglycerin.
DexmethylphenidateDexmethylphenidate may decrease the antihypertensive activities of Nitroglycerin.
DextroamphetamineDextroamphetamine may decrease the antihypertensive activities of Nitroglycerin.
DiazoxideDiazoxide may increase the hypotensive activities of Nitroglycerin.
DibenzepinDibenzepin may decrease the antihypertensive activities of Nitroglycerin.
DiclofenacThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Diclofenamide.
DiethylpropionDiethylpropion may decrease the antihypertensive activities of Nitroglycerin.
DiflunisalThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Diflunisal.
DihydralazineNitroglycerin may increase the hypotensive activities of Dihydralazine.
DihydroergocornineThe bioavailability of Dihydroergocornine can be increased when combined with Nitroglycerin.
DihydroergocristineThe bioavailability of Dihydroergocristine can be increased when combined with Nitroglycerin.
DihydroergotamineThe bioavailability of Dihydroergotamine can be increased when combined with Nitroglycerin.
DiltiazemDiltiazem may increase the vasodilatory activities of Nitroglycerin.
DinutuximabThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Dinutuximab.
DipyridamoleThe risk or severity of hypotension can be increased when Dipyridamole is combined with Nitroglycerin.
DL-MethylephedrineDL-Methylephedrine may decrease the antihypertensive activities of Nitroglycerin.
DobutamineDobutamine may decrease the antihypertensive activities of Nitroglycerin.
DopamineDopamine may decrease the antihypertensive activities of Nitroglycerin.
DopexamineDopexamine may decrease the antihypertensive activities of Nitroglycerin.
DorzolamideNitroglycerin may increase the hypotensive activities of Dorzolamide.
DosulepinDosulepin may decrease the antihypertensive activities of Nitroglycerin.
DoxapramDoxapram may decrease the antihypertensive activities of Nitroglycerin.
DoxazosinDoxazosin may increase the hypotensive activities of Nitroglycerin.
DoxepinDoxepin may decrease the antihypertensive activities of Nitroglycerin.
DronedaroneDronedarone may decrease the antihypertensive activities of Nitroglycerin.
DroperidolDroperidol may decrease the antihypertensive activities of Nitroglycerin.
DroxidopaDroxidopa may decrease the antihypertensive activities of Nitroglycerin.
DuloxetineThe risk or severity of orthostatic hypotension and syncope can be increased when Nitroglycerin is combined with Duloxetine.
DutasterideDutasteride may decrease the antihypertensive activities of Nitroglycerin.
EletriptanEletriptan may decrease the antihypertensive activities of Nitroglycerin.
EmpagliflozinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Nitroglycerin.
EnalaprilatNitroglycerin may increase the hypotensive activities of Enalaprilat.
EphedrineEphedrine may decrease the antihypertensive activities of Nitroglycerin.
EpinephrineEpinephrine may decrease the antihypertensive activities of Nitroglycerin.
EplerenoneEplerenone may increase the hypotensive activities of Nitroglycerin.
EpoprostenolEpoprostenol may increase the hypotensive activities of Nitroglycerin.
EprosartanNitroglycerin may increase the hypotensive activities of Eprosartan.
Ergoloid mesylateThe bioavailability of Ergoloid mesylate can be increased when combined with Nitroglycerin.
ErgometrineThe bioavailability of Ergometrine can be increased when combined with Nitroglycerin.
ErgotamineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Ergotamine.
EsmololEsmolol may increase the hypotensive activities of Nitroglycerin.
Etacrynic acidThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Etacrynic acid.
EtafedrineEtafedrine may decrease the antihypertensive activities of Nitroglycerin.
EthanolEthanol may increase the hypotensive and vasodilatory activities of Nitroglycerin.
EthosuximideEthosuximide may increase the vasodilatory activities of Nitroglycerin.
EtilefrineEtilefrine may decrease the antihypertensive activities of Nitroglycerin.
EtodolacThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Etodolac.
EtomidateEtomidate may decrease the antihypertensive activities of Nitroglycerin.
EtoricoxibThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Etoricoxib.
FelodipineFelodipine may increase the vasodilatory activities of Nitroglycerin.
FenbufenThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Fenbufen.
FenoldopamNitroglycerin may increase the hypotensive activities of Fenoldopam.
FenoprofenThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Fenoprofen.
FenoterolFenoterol may decrease the antihypertensive activities of Nitroglycerin.
FentanylFentanyl may decrease the antihypertensive activities of Nitroglycerin.
FinasterideFinasteride may decrease the antihypertensive activities of Nitroglycerin.
FlibanserinFlibanserin may decrease the antihypertensive activities of Nitroglycerin.
FloctafenineThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Floctafenine.
FlunarizineFlunarizine may increase the vasodilatory activities of Nitroglycerin.
FlupentixolFlupentixol may decrease the antihypertensive activities of Nitroglycerin.
FlurbiprofenThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Flurbiprofen.
FluspirileneFluspirilene may increase the vasodilatory activities of Nitroglycerin.
FlutamideThe risk or severity of methemoglobinemia can be increased when Flutamide is combined with Nitroglycerin.
FormoterolFormoterol may decrease the antihypertensive activities of Nitroglycerin.
FosinoprilFosinopril may increase the hypotensive activities of Nitroglycerin.
FostamatinibThe risk or severity of hypotension can be increased when Fostamatinib is combined with Nitroglycerin.
FrovatriptanFrovatriptan may decrease the antihypertensive activities of Nitroglycerin.
FurosemideFurosemide may increase the hypotensive activities of Nitroglycerin.
Glycol salicylateThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Glycol salicylate.
GuanabenzGuanabenz may decrease the antihypertensive activities of Nitroglycerin.
GuanadrelGuanadrel may increase the hypotensive activities of Nitroglycerin.
GuanethidineNitroglycerin may increase the hypotensive activities of Guanethidine.
GuanfacineGuanfacine may decrease the antihypertensive activities of Nitroglycerin.
GuanoxanNitroglycerin may increase the hypotensive activities of Guanoxan.
HalothaneHalothane may decrease the antihypertensive activities of Nitroglycerin.
HeparinNitroglycerin may decrease the anticoagulant activities of Heparin.
HydralazineNitroglycerin may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Nitroglycerin can be increased when used in combination with Hydrochlorothiazide.
HydroflumethiazideThe therapeutic efficacy of Nitroglycerin can be increased when used in combination with Hydroflumethiazide.
HydroxyureaThe risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Hydroxyurea.
IbuprofenThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Ibuprofen.
IcosapentThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Icosapent.
IfosfamideThe risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Ifosfamide.
IloperidoneIloperidone may decrease the antihypertensive activities of Nitroglycerin.
IloprostIloprost may increase the hypotensive activities of Nitroglycerin.
ImipramineImipramine may decrease the antihypertensive activities of Nitroglycerin.
IndacaterolIndacaterol may decrease the antihypertensive activities of Nitroglycerin.
IndapamideThe therapeutic efficacy of Indapamide can be increased when used in combination with Nitroglycerin.
IndomethacinThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Indomethacin.
IndoraminIndoramin may decrease the antihypertensive activities of Nitroglycerin.
Iofetamine I-123Iofetamine I-123 may decrease the antihypertensive activities of Nitroglycerin.
IrbesartanNitroglycerin may increase the hypotensive activities of Irbesartan.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Nitroglycerin.
IsoetharineIsoetharine may decrease the antihypertensive activities of Nitroglycerin.
IsofluraneIsoflurane may decrease the antihypertensive activities of Nitroglycerin.
IsomethepteneThe risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Isometheptene.
IsoprenalineIsoprenaline may decrease the antihypertensive activities of Nitroglycerin.
Isosorbide dinitrateThe risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Isosorbide dinitrate.
Isosorbide mononitrateNitroglycerin may increase the vasodilatory activities of Isosorbide mononitrate.
IsoxicamThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Isoxicam.
IsoxsuprineIsoxsuprine may decrease the antihypertensive activities of Nitroglycerin.
IsradipineIsradipine may increase the vasodilatory activities of Nitroglycerin.
KetoprofenThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Ketoprofen.
KetorolacThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Nitroglycerin.
LacidipineNitroglycerin may increase the hypotensive activities of Lacidipine.
LercanidipineLercanidipine may increase the vasodilatory activities of Nitroglycerin.
LevamlodipineLevamlodipine may increase the vasodilatory activities of Nitroglycerin.
LevobupivacaineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Levobupivacaine.
LevodopaThe risk or severity of hypotension and orthostatic hypotension can be increased when Nitroglycerin is combined with Levodopa.
LevonordefrinLevonordefrin may decrease the antihypertensive activities of Nitroglycerin.
LevosalbutamolLevosalbutamol may decrease the antihypertensive activities of Nitroglycerin.
LevosimendanThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Levosimendan.
LidocaineThe risk or severity of methemoglobinemia can be increased when Lidocaine is combined with Nitroglycerin.
LidoflazineLidoflazine may increase the vasodilatory activities of Nitroglycerin.
LinezolidLinezolid may increase the hypotensive activities of Nitroglycerin.
LisdexamfetamineLisdexamfetamine may decrease the antihypertensive activities of Nitroglycerin.
LisinoprilLisinopril may increase the hypotensive activities of Nitroglycerin.
LisurideThe bioavailability of Lisuride can be increased when combined with Nitroglycerin.
LofexidineLofexidine may decrease the antihypertensive activities of Nitroglycerin.
LornoxicamThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Lornoxicam.
LosartanLosartan may increase the hypotensive activities of Nitroglycerin.
LoxoprofenThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Loxoprofen.
LumiracoxibThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Lumiracoxib.
LurasidoneLurasidone may decrease the antihypertensive activities of Nitroglycerin.
MacitentanNitroglycerin may increase the hypotensive activities of Macitentan.
Magnesium sulfateMagnesium sulfate may increase the vasodilatory activities of Nitroglycerin.
ManidipineManidipine may increase the vasodilatory activities of Nitroglycerin.
MannitolThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Mannitol.
MecamylamineMecamylamine may increase the hypotensive activities of Nitroglycerin.
Meclofenamic acidThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Meclofenamic acid.
Mefenamic acidThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Mefenamic acid.
MeloxicamThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Meloxicam.
Menthyl salicylateThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Menthyl salicylate.
MephentermineMephentermine may decrease the antihypertensive activities of Nitroglycerin.
MepivacaineThe risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Mepivacaine.
MesalazineMesalazine may decrease the antihypertensive activities of Nitroglycerin.
MetamfetamineMetamfetamine may decrease the antihypertensive activities of Nitroglycerin.
MetamizoleMetamizole may decrease the antihypertensive activities of Nitroglycerin.
MetaraminolMetaraminol may decrease the antihypertensive activities of Nitroglycerin.
MetergolineThe bioavailability of Metergoline can be increased when combined with Nitroglycerin.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Nitroglycerin.
MethohexitalMethohexital may increase the hypotensive activities of Nitroglycerin.
MethotrimeprazineMethotrimeprazine may decrease the antihypertensive activities of Nitroglycerin.
MethoxamineMethoxamine may decrease the antihypertensive activities of Nitroglycerin.
MethoxyfluraneMethoxyflurane may decrease the antihypertensive activities of Nitroglycerin.
MethoxyphenamineMethoxyphenamine may decrease the antihypertensive activities of Nitroglycerin.
MethsuximideMethsuximide may increase the vasodilatory activities of Nitroglycerin.
MethyldopaNitroglycerin may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Nitroglycerin.
MethylergometrineThe bioavailability of Methylergometrine can be increased when combined with Nitroglycerin.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Nitroglycerin.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Nitroglycerin.
MethysergideThe bioavailability of Methysergide can be increased when combined with Nitroglycerin.
MetipranololNitroglycerin may increase the hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Metoclopramide.
MetolazoneMetolazone may increase the hypotensive activities of Nitroglycerin.
MetoprololMetoprolol may increase the hypotensive activities of Nitroglycerin.
MetyrosineNitroglycerin may increase the hypotensive activities of Metyrosine.
MianserinMianserin may decrease the antihypertensive activities of Nitroglycerin.
MidodrineMidodrine may decrease the antihypertensive activities of Nitroglycerin.
MinaprineMinaprine may increase the hypotensive activities of Nitroglycerin.
MinoxidilMinoxidil may increase the hypotensive activities of Nitroglycerin.
MirabegronMirabegron may decrease the antihypertensive activities of Nitroglycerin.
MirtazapineMirtazapine may decrease the antihypertensive activities of Nitroglycerin.
MoclobemideMoclobemide may increase the hypotensive activities of Nitroglycerin.
MoexiprilMoexipril may increase the hypotensive activities of Nitroglycerin.
MolsidomineMolsidomine may increase the hypotensive activities of Nitroglycerin.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Nitroglycerin.
MoxisylyteMoxisylyte may decrease the antihypertensive activities of Nitroglycerin.
MoxonidineMoxonidine may decrease the antihypertensive activities of Nitroglycerin.
MuzolimineNitroglycerin may increase the hypotensive activities of Muzolimine.
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Nitroglycerin.
NabumetoneThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Nabumetone.
NadololNitroglycerin may increase the hypotensive activities of Nadolol.
NaphazolineNaphazoline may decrease the antihypertensive activities of Nitroglycerin.
NaproxenThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Naproxen.
NaratriptanNaratriptan may decrease the antihypertensive activities of Nitroglycerin.
NaxitamabNaxitamab may decrease the antihypertensive activities of Nitroglycerin.
NebivololNitroglycerin may increase the hypotensive activities of Nebivolol.
NefazodoneNefazodone may decrease the antihypertensive activities of Nitroglycerin.
NesiritideThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nesiritide.
NialamideNialamide may increase the hypotensive activities of Nitroglycerin.
NicardipineNicardipine may increase the vasodilatory activities of Nitroglycerin.
NicergolineThe bioavailability of Nicergoline can be increased when combined with Nitroglycerin.
NicorandilNicorandil may increase the hypotensive activities of Nitroglycerin.
NifedipineNifedipine may increase the vasodilatory activities of Nitroglycerin.
NilvadipineNilvadipine may increase the vasodilatory activities of Nitroglycerin.
NimesulideNimesulide may increase the vasodilatory activities of Nitroglycerin.
NimodipineNimodipine may increase the vasodilatory activities of Nitroglycerin.
NisoldipineNisoldipine may increase the vasodilatory activities of Nitroglycerin.
NitrendipineNitrendipine may increase the vasodilatory activities of Nitroglycerin.
Nitric OxideThe risk or severity of methemoglobinemia can be increased when Nitric Oxide is combined with Nitroglycerin.
NitrofurantoinThe risk or severity of methemoglobinemia can be increased when Nitrofurantoin is combined with Nitroglycerin.
NitroprussideThe risk or severity of methemoglobinemia can be increased when Nitroprusside is combined with Nitroglycerin.
Nitrous acidThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nitrous acid.
Nitrous oxideThe risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Nitrous oxide.
NorepinephrineNorepinephrine may decrease the antihypertensive activities of Nitroglycerin.
NortriptylineNortriptyline may decrease the antihypertensive activities of Nitroglycerin.
NylidrinNylidrin may increase the vasodilatory activities of Nitroglycerin.
ObinutuzumabNitroglycerin may increase the hypotensive activities of Obinutuzumab.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Nitroglycerin.
OlmesartanOlmesartan may increase the hypotensive activities of Nitroglycerin.
OlodaterolOlodaterol may decrease the antihypertensive activities of Nitroglycerin.
OpicaponeThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Opicapone.
OrciprenalineOrciprenaline may decrease the antihypertensive activities of Nitroglycerin.
OxaprozinThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Oxaprozin.
OxprenololNitroglycerin may increase the hypotensive activities of Oxprenolol.
OxymetazolineThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Oxymetazoline.
OxyphenbutazoneThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Oxyphenbutazone.
PaclitaxelThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Paclitaxel.
PaliperidonePaliperidone may decrease the antihypertensive activities of Nitroglycerin.
PapaverineThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Papaverine.
ParecoxibThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Parecoxib.
PargylinePargyline may increase the hypotensive activities of Nitroglycerin.
Patent BlueThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Patent Blue.
PenbutololNitroglycerin may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Nitroglycerin.
PentoliniumNitroglycerin may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Nitroglycerin.
PergolideThe bioavailability of Pergolide can be increased when combined with Nitroglycerin.
PerhexilinePerhexiline may increase the vasodilatory activities of Nitroglycerin.
PericiazinePericiazine may decrease the antihypertensive activities of Nitroglycerin.
PerindoprilNitroglycerin may increase the hypotensive activities of Perindopril.
PhenazopyridineThe risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Phenazopyridine.
PhendimetrazinePhendimetrazine may decrease the antihypertensive activities of Nitroglycerin.
PhenelzinePhenelzine may increase the hypotensive activities of Nitroglycerin.
PhenmetrazinePhenmetrazine may decrease the antihypertensive activities of Nitroglycerin.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Nitroglycerin.
PhenoxybenzaminePhenoxybenzamine may decrease the antihypertensive activities of Nitroglycerin.
PhenterminePhentermine may decrease the antihypertensive activities of Nitroglycerin.
PhentolaminePhentolamine may decrease the antihypertensive activities of Nitroglycerin.
PhenylbutazoneThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Phenylbutazone.
PhenylephrinePhenylephrine may decrease the antihypertensive activities of Nitroglycerin.
PhenylpropanolaminePhenylpropanolamine may decrease the antihypertensive activities of Nitroglycerin.
PhenytoinThe risk or severity of methemoglobinemia can be increased when Phenytoin is combined with Nitroglycerin.
PinacidilNitroglycerin may increase the hypotensive activities of Pinacidil.
PinaveriumPinaverium may increase the vasodilatory activities of Nitroglycerin.
PindololNitroglycerin may increase the hypotensive activities of Pindolol.
PirbuterolPirbuterol may decrease the antihypertensive activities of Nitroglycerin.
PiroxicamThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Piroxicam.
PizotifenPizotifen may decrease the antihypertensive activities of Nitroglycerin.
PolythiazideThe therapeutic efficacy of Nitroglycerin can be increased when used in combination with Polythiazide.
PractololNitroglycerin may increase the hypotensive activities of Practolol.
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Nitroglycerin.
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Nitroglycerin.
PrenylaminePrenylamine may increase the vasodilatory activities of Nitroglycerin.
PrilocaineThe risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Prilocaine.
PrimaquineThe risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Primaquine.
PrimidonePrimidone may increase the hypotensive activities of Nitroglycerin.
ProcaineProcaine may increase the hypotensive activities of Nitroglycerin.
ProcarbazineProcarbazine may increase the hypotensive activities of Nitroglycerin.
ProcaterolProcaterol may decrease the antihypertensive activities of Nitroglycerin.
PromazinePromazine may decrease the antihypertensive activities of Nitroglycerin.
PropafenonePropafenone may decrease the antihypertensive activities of Nitroglycerin.
PropiomazinePropiomazine may decrease the antihypertensive activities of Nitroglycerin.
PropiverinePropiverine may decrease the antihypertensive activities of Nitroglycerin.
PropofolPropofol may decrease the antihypertensive activities of Nitroglycerin.
PropranololPropranolol may increase the hypotensive activities of Nitroglycerin.
ProtriptylineProtriptyline may decrease the antihypertensive activities of Nitroglycerin.
PseudoephedrinePseudoephedrine may decrease the antihypertensive activities of Nitroglycerin.
QuetiapineQuetiapine may increase the hypotensive activities of Nitroglycerin.
QuinaprilNitroglycerin may increase the hypotensive activities of Quinapril.
QuinidineQuinidine may decrease the antihypertensive activities of Nitroglycerin.
QuinineThe risk or severity of methemoglobinemia can be increased when Quinine is combined with Nitroglycerin.
QuinupramineQuinupramine may decrease the antihypertensive activities of Nitroglycerin.
RacepinephrineRacepinephrine may decrease the antihypertensive activities of Nitroglycerin.
RamiprilRamipril may increase the hypotensive activities of Nitroglycerin.
RasagilineRasagiline may increase the hypotensive activities of Nitroglycerin.
RasburicaseThe risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Nitroglycerin.
RemifentanilRemifentanil may decrease the antihypertensive activities of Nitroglycerin.
RescinnamineRescinnamine may decrease the antihypertensive activities of Nitroglycerin.
ReserpineReserpine may increase the hypotensive activities of Nitroglycerin.
ReteplaseThe therapeutic efficacy of Reteplase can be decreased when used in combination with Nitroglycerin.
RilmenidineRilmenidine may decrease the antihypertensive activities of Nitroglycerin.
RiociguatNitroglycerin may increase the hypotensive activities of Riociguat.
RisperidoneNitroglycerin may increase the hypotensive activities of Risperidone.
RitodrineRitodrine may decrease the antihypertensive activities of Nitroglycerin.
RituximabNitroglycerin may increase the hypotensive activities of Rituximab.
RizatriptanRizatriptan may decrease the antihypertensive activities of Nitroglycerin.
RofecoxibThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Rofecoxib.
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Nitroglycerin.
RopivacaineThe risk or severity of methemoglobinemia can be increased when Ropivacaine is combined with Nitroglycerin.
RosiglitazoneThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Rosiglitazone.
RotigotineRotigotine may decrease the antihypertensive activities of Nitroglycerin.
SacubitrilThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Sacubitril.
SafinamideSafinamide may increase the hypotensive activities of Nitroglycerin.
SalicylamideThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Salicylamide.
Salicylic acidThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Salicylic acid.
SalmeterolSalmeterol may decrease the antihypertensive activities of Nitroglycerin.
SalsalateThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Salsalate.
SecobarbitalSecobarbital may increase the hypotensive activities of Nitroglycerin.
SelegilineSelegiline may increase the hypotensive activities of Nitroglycerin.
SelexipagNitroglycerin may increase the hypotensive activities of Selexipag.
SelpercatinibSelpercatinib may decrease the antihypertensive activities of Nitroglycerin.
SerdexmethylphenidateThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Serdexmethylphenidate.
SevofluraneSevoflurane may decrease the antihypertensive activities of Nitroglycerin.
SildenafilThe risk or severity of hypotension can be increased when Nitroglycerin is combined with Sildenafil.
SilodosinThe risk or severity of orthostatic hypotension and dizziness can be increased when Nitroglycerin is combined with Silodosin.
SiponimodSiponimod may decrease the antihypertensive activities of Nitroglycerin.
SitaxentanNitroglycerin may increase the hypotensive activities of Sitaxentan.
Sodium ferric gluconate complexThe risk or severity of hypotension can be increased when Sodium ferric gluconate complex is combined with Nitroglycerin.
SolifenacinSolifenacin may decrease the antihypertensive activities of Nitroglycerin.
SolriamfetolSolriamfetol may decrease the antihypertensive activities of Nitroglycerin.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Nitroglycerin.
SpiraprilNitroglycerin may increase the hypotensive activities of Spirapril.
SpironolactoneSpironolactone may increase the hypotensive activities of Nitroglycerin.
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Nitroglycerin.
SufentanilSufentanil may decrease the antihypertensive activities of Nitroglycerin.
SulfadiazineThe risk or severity of methemoglobinemia can be increased when Sulfadiazine is combined with Nitroglycerin.
SulfamethoxazoleThe risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Sulfamethoxazole.
SulfapyridineThe risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Sulfapyridine.
SulfasalazineThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Sulfasalazine.
SulindacThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Sulindac.
SumatriptanSumatriptan may decrease the antihypertensive activities of Nitroglycerin.
TadalafilThe risk or severity of hypotension can be increased when Tadalafil is combined with Nitroglycerin.
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Nitroglycerin.
TelmisartanNitroglycerin may increase the hypotensive activities of Telmisartan.
TenecteplaseThe therapeutic efficacy of Tenecteplase can be decreased when used in combination with Nitroglycerin.
TenoxicamThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Tenoxicam.
TerazosinNitroglycerin may increase the hypotensive activities of Terazosin.
TerbutalineTerbutaline may decrease the antihypertensive activities of Nitroglycerin.
TetracaineThe risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Tetracaine.
TetryzolineTetryzoline may decrease the antihypertensive activities of Nitroglycerin.
ThalidomideThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Thalidomide.
ThiamylalThiamylal may increase the hypotensive activities of Nitroglycerin.
ThiopentalThiopental may increase the hypotensive activities of Nitroglycerin.
ThioridazineThioridazine may decrease the antihypertensive activities of Nitroglycerin.
Tiaprofenic acidThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Tiaprofenic acid.
TimololTimolol may increase the hypotensive activities of Nitroglycerin.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Nitroglycerin.
TolazolineTolazoline may decrease the antihypertensive activities of Nitroglycerin.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Nitroglycerin.
Tolfenamic acidThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Tolfenamic acid.
TolmetinThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Tolmetin.
TorasemideTorasemide may increase the hypotensive activities of Nitroglycerin.
TrandolaprilTrandolapril may increase the hypotensive activities of Nitroglycerin.
TranylcypromineTranylcypromine may increase the hypotensive activities of Nitroglycerin.
TrazodoneTrazodone may decrease the antihypertensive activities of Nitroglycerin.
TreprostinilTreprostinil may increase the hypotensive activities of Nitroglycerin.
TretinoinTretinoin may decrease the antihypertensive activities of Nitroglycerin.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nitroglycerin.
TrichlormethiazideThe therapeutic efficacy of Nitroglycerin can be increased when used in combination with Trichlormethiazide.
TrichloroethyleneTrichloroethylene may decrease the antihypertensive activities of Nitroglycerin.
TrifluoperazineTrifluoperazine may decrease the antihypertensive activities of Nitroglycerin.
TrimebutineTrimebutine may increase the vasodilatory activities of Nitroglycerin.
TrimethadioneTrimethadione may increase the vasodilatory activities of Nitroglycerin.
TrimethaphanNitroglycerin may increase the hypotensive activities of Trimethaphan.
TrimipramineTrimipramine may decrease the antihypertensive activities of Nitroglycerin.
UdenafilThe risk or severity of hypotension can be increased when Udenafil is combined with Nitroglycerin.
UnoprostoneNitroglycerin may increase the hypotensive activities of Unoprostone.
ValdecoxibThe therapeutic efficacy of Nitroglycerin can be decreased when used in combination with Valdecoxib.
Valproic acidThe risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Nitroglycerin.
ValsartanValsartan may increase the hypotensive activities of Nitroglycerin.
VardenafilThe risk or severity of hypotension can be increased when Vardenafil is combined with Nitroglycerin.
VerapamilVerapamil may increase the vasodilatory activities of Nitroglycerin.
VericiguatThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Vericiguat.
VilanterolVilanterol may decrease the antihypertensive activities of Nitroglycerin.
VilazodoneVilazodone may decrease the antihypertensive activities of Nitroglycerin.
VortioxetineVortioxetine may decrease the antihypertensive activities of Nitroglycerin.
XamoterolXamoterol may decrease the antihypertensive activities of Nitroglycerin.
XylometazolineXylometazoline may decrease the antihypertensive activities of Nitroglycerin.
YohimbineYohimbine may decrease the antihypertensive activities of Nitroglycerin.
ZiprasidoneZiprasidone may increase the antihypertensive activities of Nitroglycerin.
ZofenoprilNitroglycerin may increase the hypotensive activities of Zofenopril.
ZolmitriptanZolmitriptan may decrease the antihypertensive activities of Nitroglycerin.
ZonisamideZonisamide may increase the vasodilatory activities of Nitroglycerin.
ZopicloneThe risk or severity of methemoglobinemia can be increased when Nitroglycerin is combined with Zopiclone.
ZuclopenthixolZuclopenthixol may decrease the antihypertensive activities of Nitroglycerin.
Food Interactions
  • Avoid alcohol. Alcohol can increase the risk of hypotension.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Images
International/Other Brands
Deponit (UCB Pharma) / Dermatrans (Bayer) / Gen-Nitro (Genpharm ULC) / Glytrin (Sanofi-Aventis) / Glytrin Spray (Sanofi-Aventis) / Natispray (Teofarma) / Nitrocap (Orion) / Nitroderm TTS (Novartis) / Nitrolingual Pump Spray (Arbor Pharmaceuticals) / Rectogesic (ProStrakan) / Stangyl / Transderm-Nitro (Novartis) / Tridil / Trimonit (Sanofi-Aventis) / Trinipatch (Paladin) / Triniplas (Novartis) / Trinispray (Sanofi Aventis) / Trinitrin Simplex Laleuf (Sanofi) / Trinitron (Quesada) / Trinitrosan (Merck) / Trintek (Goldshield) / Trocer (Incepta) / Trocer SR (Incepta) / Vasolator (Sanwa Kagaku) / Vasovin (Torrent) / Venitrin (Meda) / Vernies (Parke Davis) / Willlong (Will-Pharma)
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
GonitroPowder400 ug/1SublingualEspero Pharmaceuticals, Inc.2016-07-01Not applicableUS flag
GonitroPowder400 ug/1SublingualAllegis Pharmaceuticals, Inc.2019-07-012023-06-30US flag
MinitranPatch0.6 mg / hourTransdermalValeant Canada Lp Valeant Canada S.E.C.1995-12-312021-03-19Canada flag
MinitranPatch18 mg/1TransdermalKindeva Drug Delivery L.P.2012-02-21Not applicableUS flag
MinitranPatch54 mg/1TransdermalKindeva Drug Delivery L.P.2012-02-21Not applicableUS flag
MinitranPatch0.2 mg / hourTransdermalValeant Canada Lp Valeant Canada S.E.C.1995-12-312021-03-19Canada flag
MinitranPatch0.4 mg / hourTransdermalValeant Canada Lp Valeant Canada S.E.C.1995-12-312021-03-19Canada flag
MinitranPatch36 mg/1TransdermalKindeva Drug Delivery L.P.2012-02-21Not applicableUS flag
Minitran - Patch Trd 72mg/26.6 Sq CmPatch72 mg / 26.6 sq cmTransdermalGraceway PharmaceuticalsNot applicableNot applicableCanada flag
Nitro-durPatch20 mg/1TransdermalIngenus Pharmaceuticals, LLC2017-12-06Not applicableUS flag
Nitro-durPatch80 mg/1TransdermalIngenus Pharmaceuticals, LLC2017-12-06Not applicableUS flag
Nitro-durPatch60 mg/1TransdermalIngenus Pharmaceuticals, LLC2017-12-06Not applicableUS flag
Nitro-durPatch120 mg/1TransdermalMerck Sharp & Dohme Corp.1995-04-042017-06-02US flag
Nitro-durPatch40 mg/1TransdermalMerck Sharp & Dohme Corp.1995-04-042017-06-02US flag
Nitro-durPatch160 mg/1TransdermalIngenus Pharmaceuticals, LLC2017-12-06Not applicableUS flag
Nitro-durPatch40 mg/1TransdermalPhysicians Total Care, Inc.1993-08-132005-12-31US flag
Nitro-durPatch40 mg/1TransdermalIngenus Pharmaceuticals, LLC2017-12-06Not applicableUS flag
Nitro-durPatch80 mg/1TransdermalMerck Sharp & Dohme Corp.1995-04-042017-06-02US flag
Nitro-durPatch20 mg/1TransdermalMerck Sharp & Dohme Corp.1995-04-042017-06-02US flag
Nitro-durPatch120 mg/1TransdermalIngenus Pharmaceuticals, LLC2017-12-06Not applicableUS flag
Nitro-durPatch20 mg/1TransdermalPhysicians Total Care, Inc.1995-07-262005-12-31US flag
Nitro-durPatch160 mg/1TransdermalMerck Sharp & Dohme Corp.1995-04-042017-06-02US flag
Nitro-durPatch60 mg/1TransdermalMerck Sharp & Dohme Corp.1995-04-042017-06-02US flag
Nitro-dur 0.2Patch, extended release0.2 mg / hourTransdermalUspharma Ltd1991-12-31Not applicableCanada flag
Nitro-dur 0.3 - 60mg/15 Sq Cm, 0.3mg/hrPatch, extended release60 mg / 15 sq cmTransdermalKey Pharmaceuticals, Division Of Schering Plough Canada Inc.1996-09-052004-07-20Canada flag
Nitro-dur 0.4Patch, extended release0.4 mg / hourTransdermalUspharma Ltd1991-12-31Not applicableCanada flag
Nitro-dur 0.6Patch, extended release0.6 mg / hourTransdermalUspharma Ltd1991-12-31Not applicableCanada flag
Nitro-dur 0.8Patch, extended release0.8 mg / hourTransdermalUspharma Ltd1993-12-31Not applicableCanada flag
Nitro-TimeCapsule2.5 mg/1OralMajor Pharmaceuticals2004-01-292022-10-31US flag
Nitro-TimeCapsule6.5 mg/1OralAvera McKennan Hospital2015-04-242017-05-24US flag
Nitro-timeCapsule2.5 mg/1OralTIME CAP LABORATORIES, INC2014-06-19Not applicableUS flag
Nitro-TimeCapsule9.0 mg/1OralMajor Pharmaceuticals2004-01-292022-12-31US flag
Nitro-timeCapsule9 mg/1OralTIME CAP LABORATORIES, INC2014-06-19Not applicableUS flag
Nitro-TimeCapsule2.5 mg/1OralCarilion Materials Management2004-01-29Not applicableUS flag
Nitro-TimeCapsule6.5 mg/1OralMajor Pharmaceuticals2004-01-292022-02-28US flag
Nitro-timeCapsule6.5 mg/1OralTIME CAP LABORATORIES, INC2014-06-19Not applicableUS flag
Nitro-TimeCapsule6.5 mg/1OralCarilion Materials Management2004-01-29Not applicableUS flag
Nitrogard-SR Tab 1mgTablet, extended release1 mgBuccalAstra Pharma Inc.1987-12-311996-11-13Canada flag
NitroglycerinInjection, solution, concentrate5 mg/1mLIntravenousHospira, Inc.1981-10-062012-01-19US flag
NitroglycerinTablet0.6 mg/1OralGlenmark Generics, Inc. USA2005-03-032010-09-01US flag
NitroglycerinSpray400 ug/1OralHF Acquisition Co LLC, DBA HealthFirst2018-11-27Not applicableUS flag
NitroglycerinCapsule6.5 mg/1OralPD-Rx Pharmaceuticals, Inc.2014-06-19Not applicableUS flag
NitroglycerinTablet0.4 mg/1OralPreferred Pharmaceuticals, Inc2005-03-032019-01-25US flag
NitroglycerinCapsule2.5 mg/1OralPD-Rx Pharmaceuticals, Inc.2014-06-19Not applicableUS flag
NitroglycerinCapsule9.0 mg/1OralCarilion Materials Management2004-01-29Not applicableUS flag
NitroglycerinTablet0.4 mg/1OralGlenmark Generics, Inc. USA2005-03-032010-09-01US flag
NitroglycerinInjection, solution, concentrate5 mg/1mLIntravenousHospira, Inc.1981-10-062010-12-29US flag
NitroglycerinTablet0.4 mg/1OralRebel Distributors2005-03-03Not applicableUS flag
NitroglycerinCapsule9 mg/1OralPD-Rx Pharmaceuticals, Inc.2014-06-19Not applicableUS flag
NitroglycerinSpray400 ug/1OralHf Acquisition Co. Llc, Dba Health First2018-08-18Not applicableUS flag
NitroglycerinTablet0.3 mg/1OralGlenmark Generics, Inc. USA2005-03-032010-09-01US flag
Nitroglycerin ERCapsule2.5 mg/1OralAvKARE2012-12-19Not applicableUS flag
Nitroglycerin ERCapsule9 mg/1OralPD-Rx Pharmaceuticals, Inc.2010-05-10Not applicableUS flag
Nitroglycerin ERCapsule6.5 mg/1OralPD-Rx Pharmaceuticals, Inc.2010-05-10Not applicableUS flag
Nitroglycerin ERCapsule2.5 mg/1OralPD-Rx Pharmaceuticals, Inc.2014-06-20Not applicableUS flag
Nitroglycerin ERCapsule6.5 mg/1OralAvKARE2012-12-192021-01-31US flag
Nitroglycerin In DextroseInjection10 mg/100mLIntravenousBaxter Healthcare Company1989-12-29Not applicableUS flag
Nitroglycerin In DextroseInjection40 mg/100mLIntravenousBaxter Healthcare Company1989-12-29Not applicableUS flag
Nitroglycerin In DextroseInjection20 mg/100mLIntravenousHF Acquisition Co LLC, DBA HealthFirst2018-11-26Not applicableUS flag
Nitroglycerin In DextroseInjection20 mg/100mLIntravenousBaxter Healthcare Company1989-12-29Not applicableUS flag
Nitroglycerin Inj 5mg/mlLiquid5 mg / mLIntravenousDavid Bull Laboratories (Pty) Ltd.1988-12-312000-08-01Canada flag
Nitroglycerin Injection USPSolution50 mg / 10 mLIntravenousMont Pharma IncNot applicableNot applicableCanada flag
Nitroglycerin Injection USPSolution50 mg / 10 mLIntravenousSandoz Canada Incorporated1993-12-312019-08-01Canada flag
Nitroglycerin LingualSpray, metered400 ug/1SublingualWilshire Pharmaceuticals, Inc.2011-02-012018-02-28US flag
Nitroglycerin LingualSpray400 ug/1OralJacksonville Pharmaceuticals, Inc.2016-03-01Not applicableUS flag
Nitroglycerin LingualSpray400 ug/1OralHF Acquisition Co LLC, DBA HealthFirst2020-06-25Not applicableUS flag
Nitroglycerin SlocapsCapsule9 mg/1OralEon Labs, Inc.1984-06-202011-05-31US flag
Nitroglycerin SlocapsCapsule6.5 mg/1OralRebel Distributors1982-08-25Not applicableUS flag
Nitroglycerin SlocapsCapsule6.5 mg/1OralEon Labs, Inc.1982-08-252011-05-31US flag
Nitroglycerin SlocapsCapsule2.5 mg/1OralRebel Distributors1982-08-25Not applicableUS flag
Nitroglycerin SlocapsCapsule2.5 mg/1OralEon Labs, Inc.1982-08-252011-05-31US flag
Nitroglycerin SRCapsule6.5 mg/1OralPhysicians Total Care, Inc.1995-12-202011-06-30US flag
NitrojectSolution50 mg / 10 mLIntravenousOmega Laboratories Limited1988-12-31Not applicableCanada flag
Nitroject Inj 1mg/mlSolution10 mg / 10 mLIntravenousOmega Laboratories Limited1990-12-312022-06-20Canada flag
NitrolOintment2 %TopicalPaladin Labs Inc1985-12-312018-04-19Canada flag
NitrolingualSpray, metered400 ug/1SublingualPhysicians Total Care, Inc.2002-06-032011-05-31US flag
NitrolingualSpray400 ug/1OralFIRST HORIZON PHARMACEUTICAL CORPORATION2006-06-02Not applicableUS flag
NitrolingualSpray400 ug/1OralRebel Distributors1985-10-312011-09-30US flag
NitrolingualSpray400 ug/1OralEspero Pharmaceuticals, Inc.2016-03-01Not applicableUS flag
NitrolingualSpray400 ug/1OralAllegis Pharmaceuticals, LLC2019-07-01Not applicableUS flag
Nitrolingual PumpspraySpray, metered400 ug/1OralArbor Pharmaceuticals2000-02-012017-10-31US flag
Nitrolingual PumpspraySpray, metered0.4 mg / actSublingualSanofi Aventis1998-07-31Not applicableCanada flag
Nitrolingual Spray 0.4mg/eamAerosol, metered0.4 mg / actSublingualAventis Pharma Ltd.1986-12-312001-07-20Canada flag
NitroMistAerosol, metered400 ug/1SublingualMist Pharmaceuticals, Llc2016-01-25Not applicableUS flag
NitroMistAerosol, spray400 ug/1TransmucosalNovaDel Pharma Inc.2007-03-30Not applicableUS flag
NitroMistAerosol, metered400 ug/1SublingualAkrimax Pharmaceuticals, LLC2010-05-012018-05-31US flag
NitroMistAerosol, metered400 ug/1SublingualEvus Pharmaceuticals, LLC2016-01-25Not applicableUS flag
NitronalInjection, solution1 mg/1mLIntravenousG. POHL-BOSKAMP GmbH & Co. KG2014-04-072016-03-22US flag
Nitrong SR Srt 2.6mgTablet, extended release2.6 mgOralMetro Pharm Inc.1964-12-312005-09-15Canada flag
NitrostatTablet0.3 mg/1SublingualParke-Davis Div of Pfizer Inc2000-05-01Not applicableUS flag
NitrostatTablet0.4 mg/1SublingualA S Medication Solutions2000-05-01Not applicableUS flag
NitrostatTablet0.4 mg/1SublingualGeneral Injectables & Vaccines, Inc2010-03-012023-10-31US flag
NitrostatTablet0.4 mg/1SublingualProficient Rx LP2000-05-01Not applicableUS flag
NitrostatTablet0.3 mg/1OralPhysicians Total Care, Inc.1994-09-22Not applicableUS flag
NitrostatTablet0.4 mg/1SublingualViatris Specialty Llc2024-02-02Not applicableUS flag
NitrostatTablet0.4 mg/1SublingualAidarex Pharmaceuticals LLC2000-05-01Not applicableUS flag
NitrostatTablet0.4 mg/1SublingualA S Medication Solutions2000-05-01Not applicableUS flag
NitrostatTablet0.4 mg/1SublingualSina Health Inc2000-05-01Not applicableUS flag
NitrostatTablet0.6 mg/1SublingualParke-Davis Div of Pfizer Inc2000-05-012025-04-30US flag
NitrostatTablet0.4 mg/1SublingualCardinal Health2000-05-012019-07-31US flag
NitrostatTablet0.4 mg/1SublingualNucare Pharmaceuticals,inc.2000-05-01Not applicableUS flag
NitrostatTablet0.4 mg/1SublingualREMEDYREPACK INC.2014-06-272016-10-03US flag
NitrostatTablet0.4 mg/1SublingualHenry Schein, Inc.2023-02-23Not applicableUS flag
NitrostatTablet0.6 mg/1OralPhysicians Total Care, Inc.1994-12-162011-03-31US flag
NitrostatTablet0.4 mg/1SublingualParke-Davis Div of Pfizer Inc2000-05-012025-02-28US flag
NitrostatTablet0.4 mg/1SublingualRebel Distributors2000-05-01Not applicableUS flag
NitrostatTablet0.3 mg/1SublingualViatris Specialty Llc2024-02-02Not applicableUS flag
NitrostatTablet0.3 mgSublingualBgp Pharma Ulc1972-12-31Not applicableCanada flag
NitrostatTablet0.4 mg/1OralPhysicians Total Care, Inc.1995-08-11Not applicableUS flag
NitrostatTablet0.4 mg/1SublingualREMEDYREPACK INC.2017-01-06Not applicableUS flag
NitrostatTablet0.4 mg/1SublingualRemedy Repack2012-12-312014-04-02US flag
NitrostatTablet0.4 mg/1SublingualA-S Medication Solutions2000-05-01Not applicableUS flag
NitrostatTablet0.6 mgSublingualBgp Pharma Ulc1972-12-31Not applicableCanada flag
NitrostatTablet0.4 mg/1SublingualA-S Medication Solutions2000-05-01Not applicableUS flag
NitrostatTablet0.4 mg/1SublingualPreferred Pharmaceuticals, Inc.2013-05-152019-01-25US flag
NitrostatTablet0.6 mg/1SublingualViatris Specialty Llc2024-02-09Not applicableUS flag
RectivOintment4 mg/1gRectalAllergan, Inc.2011-06-21Not applicableUS flag
RectivOintment4 mg/1gRectalProStrakan, Inc.2011-06-21Not applicableUS flag
Transderm NitroPatch, extended release50 mg/1TransdermalNovartis1996-02-272008-09-14US flag
Transderm NitroPatch, extended release25 mg/1TransdermalNovartis1996-02-272008-09-14US flag
Transderm NitroPatch, extended release75 mg/1TransdermalNovartis1996-02-272008-09-14US flag
Transderm NitroPatch, extended release12.5 mg/1TransdermalNovartis1996-02-272008-09-14US flag
Transderm-nitro 0.2Patch, extended release0.2 mg / hourTransdermalNovartis1989-12-312022-04-05Canada flag
Transderm-nitro 0.4Patch, extended release0.4 mg / hourTransdermalNovartis1989-12-312022-04-05Canada flag
Transderm-nitro 0.6Patch, extended release0.6 mg / hourTransdermalNovartis1994-12-312022-04-05Canada flag
Transderm-nitro 0.8Patch, extended release100 mg / srdTransdermalNovartis1994-12-311999-08-04Canada flag
Tridil Injection 5mg/mlLiquid5 mg / mLIntravenousDupont Pharma Inc.1993-12-312001-08-07Canada flag
Trinipatch 0.2Patch0.2 mg / hourTransdermalPaladin Labs Inc1999-04-01Not applicableCanada flag
Trinipatch 0.4Patch0.4 mg / hourTransdermalPaladin Labs Inc1999-04-01Not applicableCanada flag
Trinipatch 0.6Patch0.6 mg / hourTransdermalPaladin Labs Inc1999-04-01Not applicableCanada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Apo-nitroglycerinSpray, metered0.4 mg / actSublingualApotex Corporation2013-09-23Not applicableCanada flag
MinitranPatch36000 ug/1Transdermal3M Company1996-08-302006-12-29US flag
MinitranPatch36 mg/1TransdermalBausch Health US, LLC2012-02-212020-11-03US flag
MinitranPatch18 mg/1TransdermalBausch Health US, LLC2012-02-212021-01-01US flag
MinitranPatch10 mg/1dTransdermalGraceway Pharmaceuticals2009-08-10Not applicableUS flag
MinitranPatch18000 ug/1Transdermal3M Company1996-08-302006-12-29US flag
MinitranPatch18 mg/1[USP'U]TransdermalPhysicians Total Care, Inc.2012-02-212012-06-30US flag
MinitranPatch9 mg/1TransdermalBausch Health US, LLC2012-02-212021-10-01US flag
MinitranPatch54000 ug/1Transdermal3M Company1996-08-302006-12-29US flag
MinitranPatch5 mg/1dTransdermalGraceway Pharmaceuticals2007-04-01Not applicableUS flag
MinitranPatch9000 ug/1Transdermal3M Company1996-08-302006-12-29US flag
MinitranPatch2.5 mg/1dTransdermalGraceway Pharmaceuticals2007-04-01Not applicableUS flag
MinitranPatch54 mg/1TransdermalBausch Health US, LLC2012-02-212021-03-02US flag
MinitranPatch15 mg/1dTransdermalGraceway Pharmaceuticals2007-04-01Not applicableUS flag
Mylan-nitro Patch 0.2Patch, extended release0.2 mg / hourTransdermalMylan Pharmaceuticals2013-06-04Not applicableCanada flag
Mylan-nitro Patch 0.4Patch, extended release0.4 mg / hourTransdermalMylan Pharmaceuticals2013-06-04Not applicableCanada flag
Mylan-nitro Patch 0.6Patch, extended release0.6 mg / hourTransdermalMylan Pharmaceuticals2013-06-04Not applicableCanada flag
Mylan-nitro Patch 0.8Patch, extended release0.8 mg / hourTransdermalMylan Pharmaceuticals2013-06-04Not applicableCanada flag
Mylan-nitro Sublingual SprayAerosol, metered0.4 mg / actSublingualMylan Pharmaceuticals2001-08-23Not applicableCanada flag
Nitro-bidOintment20 mg/1gTopicalSavage Laboratories a division of Fougera Pharmaceuticals Inc.2009-08-15Not applicableUS flag
Nitro-bidOintment20 mg/1gTopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2009-08-152011-11-30US flag
Nitro-bidOintment20 mg/1gTopicalPhysicians Total Care, Inc.2009-08-152011-05-31US flag
NitroglycerinTablet0.3 mg/1SublingualZydus Pharmaceuticals (USA) Inc.2023-02-02Not applicableUS flag
NitroglycerinInjection, solution5 mg/1mLIntravenousGeneral Injectables and Vaccines, Inc.2010-06-012023-11-30US flag
NitroglycerinOintment4 mg/1gRectalCosette Pharmaceuticals, Inc.2024-02-23Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualHF Acquisition Co LLC, DBA HealthFirst2021-05-11Not applicableUS flag
NitroglycerinTablet0.3 mg/1SublingualAdvagen Pharma Ltd2021-05-03Not applicableUS flag
NitroglycerinTablet0.3 mg/1SublingualSigmapharm Laboratories, LLC2021-05-07Not applicableUS flag
NitroglycerinTablet0.6 mg/1SublingualNatco Pharma USA LLC2022-10-03Not applicableUS flag
NitroglycerinTablet, orally disintegrating0.3 mg/1SublingualGreenstone LLC2016-08-26Not applicableUS flag
NitroglycerinAerosol, metered400 ug/1SublingualRouses Point Pharm2012-10-16Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualLifestar Pharma Llc2023-12-05Not applicableUS flag
NitroglycerinPatch0.1 mg/1hTransdermalMylan Pharmaceuticals Inc.1998-06-18Not applicableUS flag
NitroglycerinTablet0.6 mg/1SublingualDr Reddy's Laboratories2016-08-29Not applicableUS flag
NitroglycerinInjection, solution5 mg/1mLIntravenousHF Acquisition Co LLC, DBA HealthFirst2019-10-07Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualMedical Purchasing Solutions, LL2022-10-03Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualNucare Pharmaceuticals,inc.2019-04-30Not applicableUS flag
NitroglycerinInjection, solution5 mg/1mLIntravenousHenry Schein, Inc.2022-01-13Not applicableUS flag
NitroglycerinTablet, orally disintegrating0.4 mg/1SublingualPhysicians Total Care, Inc.2009-06-25Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualA-S Medication Solutions2017-09-19Not applicableUS flag
NitroglycerinTablet0.6 mg/1SublingualGlenmark Pharmaceuticals Inc., USA2017-09-19Not applicableUS flag
NitroglycerinTablet0.6 mg/1SublingualIngenus Pharmaceuticals Nj, Llc2016-08-262016-08-26US flag
NitroglycerinTablet0.4 mg/1SublingualA-S Medication Solutions2016-08-29Not applicableUS flag
NitroglycerinFilm, extended release37.4 mg/1TransdermalKremers Urban2004-08-10Not applicableUS flag
NitroglycerinTablet0.3 mg/1SublingualAurobindo Pharma Limited2023-10-26Not applicableUS flag
NitroglycerinInjection, solution5 mg/1mLIntravenousCardinal Health2003-03-042016-08-31US flag
NitroglycerinTablet0.3 mg/1SublingualGolden State Medical Supply, Inc.2016-08-26Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualNucare Pharmaceuticals,inc.2016-08-29Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualREMEDYREPACK INC.2017-09-07Not applicableUS flag
NitroglycerinTablet0.6 mg/1SublingualAdvagen Pharma Ltd2021-05-03Not applicableUS flag
NitroglycerinPatch0.4 mg/1hTransdermalMylan Pharmaceuticals Inc.1996-08-30Not applicableUS flag
NitroglycerinTablet0.6 mg/1SublingualAlvogen Inc.2019-04-302024-06-01US flag
NitroglycerinTablet0.4 mg/1Sublingualbryant ranch prepack2019-04-302023-08-01US flag
NitroglycerinInjection, solution5 mg/1mLIntravenousPhysicians Total Care, Inc.2006-12-112011-06-30US flag
NitroglycerinTablet0.4 mg/1SublingualZydus Lifesciences Limited2023-02-02Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualMedical Purchasing Solutions, Llc2017-09-19Not applicableUS flag
NitroglycerinTablet0.6 mg/1SublingualSigmapharm Laboratories, LLC2021-05-07Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualProficient Rx LP2016-08-29Not applicableUS flag
NitroglycerinTablet0.6 mg/1SublingualZydus Pharmaceuticals (USA) Inc.2023-02-02Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualGlenmark Pharmaceuticals Inc., USA2017-09-19Not applicableUS flag
NitroglycerinTablet, orally disintegrating0.6 mg/1SublingualGreenstone LLC2016-08-26Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualA-S Medication Solutions2019-04-302024-06-01US flag
NitroglycerinTablet0.4 mg/1SublingualProficient Rx LP2022-10-03Not applicableUS flag
NitroglycerinTablet0.3 mg/1SublingualAlvogen Inc.2019-04-302024-06-01US flag
NitroglycerinTablet0.4 mg/1SublingualNatco Pharma USA LLC2022-10-03Not applicableUS flag
NitroglycerinPatch0.6 mg/1hTransdermalMylan Pharmaceuticals Inc.1996-08-30Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualPreferred Pharmaceuticals Inc.2017-01-232019-01-25US flag
NitroglycerinTablet0.3 mg/1SublingualLifestar Pharma Llc2023-12-05Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualDr Reddy's Laboratories2016-08-29Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualNucare Pharmaceuticals,inc.2022-10-03Not applicableUS flag
NitroglycerinInjection, solution5 mg/1mLIntravenousAMERICAN REGENT, INC.2003-03-04Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualREMEDYREPACK INC.2020-10-19Not applicableUS flag
NitroglycerinTablet0.6 mg/1SublingualAurobindo Pharma Limited2023-10-26Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualIngenus Pharmaceuticals Nj, Llc2016-08-262016-08-26US flag
NitroglycerinTablet0.6 mg/1SublingualGolden State Medical Supply, Inc.2016-08-26Not applicableUS flag
NitroglycerinTablet0.3 mg/1SublingualZydus Lifesciences Limited2023-02-02Not applicableUS flag
NitroglycerinTablet, orally disintegrating0.4 mg/1SublingualSina Health Inc2016-08-26Not applicableUS flag
NitroglycerinFilm, extended release20.8 mg/1TransdermalKremers Urban2004-08-10Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualREMEDYREPACK INC.2022-12-21Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualZydus Pharmaceuticals (USA) Inc.2023-02-02Not applicableUS flag
NitroglycerinTablet, orally disintegrating0.4 mg/1SublingualGreenstone LLC2016-08-26Not applicableUS flag
NitroglycerinPatch0.2 mg/1hTransdermalMylan Pharmaceuticals Inc.1996-08-30Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualAdvagen Pharma Ltd2021-05-03Not applicableUS flag
NitroglycerinTablet0.3 mg/1SublingualNatco Pharma USA LLC2022-10-03Not applicableUS flag
NitroglycerinTablet0.3 mg/1Sublingualbryant ranch prepack2019-04-302024-01-01US flag
NitroglycerinTablet0.4 mg/1SublingualNucare Pharmaceuticals,inc.2017-09-19Not applicableUS flag
NitroglycerinOintment20 mg/1gTopicalHF Acquisition Co LLC, DBA HealthFirst2018-12-22Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualSigmapharm Laboratories, LLC2021-05-07Not applicableUS flag
NitroglycerinTablet0.3 mg/1SublingualGlenmark Pharmaceuticals Inc., USA2017-08-19Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualMedical Purchasing Solutions, Llc2019-04-302024-05-31US flag
NitroglycerinTablet0.4 mg/1SublingualProficient Rx LP2019-04-30Not applicableUS flag
NitroglycerinTablet0.6 mg/1SublingualLifestar Pharma Llc2023-12-05Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualAlvogen Inc.2019-04-302024-06-01US flag
NitroglycerinTablet0.3 mg/1SublingualDr Reddy's Laboratories2016-08-29Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualMedical Purchasing Solutions, Llc2016-08-29Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualREMEDYREPACK INC.2020-06-102024-04-01US flag
NitroglycerinTablet0.6 mg/1SublingualZydus Lifesciences Limited2023-02-02Not applicableUS flag
NitroglycerinTablet0.3 mg/1SublingualIngenus Pharmaceuticals Nj, Llc2016-08-262016-08-26US flag
NitroglycerinTablet0.4 mg/1SublingualGolden State Medical Supply, Inc.2016-08-26Not applicableUS flag
NitroglycerinTablet0.4 mg/1SublingualAurobindo Pharma Limited2023-10-26Not applicableUS flag
NitroglycerinTablet0.4 mg/1Sublingualbryant ranch prepack2019-04-302024-06-01US flag
Nitroglycerin in DextroseInjection, solution200 ug/1mLIntravenousHospira, Inc.2005-04-302013-06-01US flag
Nitroglycerin in DextroseInjection, solution400 ug/1mLIntravenousHospira, Inc.2005-04-302012-09-01US flag
Nitroglycerin in DextroseInjection, solution100 ug/1mLIntravenousHospira, Inc.2005-03-312013-05-01US flag
Nitroglycerin LingualSpray400 ug/1OralPadagis Israel Pharmaceuticals Ltd2013-09-20Not applicableUS flag
Nitroglycerin LingualSpray400 ug/1OralAllegis Pharmaceuticals, LLC2019-07-01Not applicableUS flag
Nitroglycerin LingualSpray400 ug/1OralHF Acquisition Co LLC, DBA HealthFirst2019-10-09Not applicableUS flag
Nitroglycerin LingualSpray400 ug/1OralHF Acquisition Co LLC, DBA HealthFirst2019-10-09Not applicableUS flag
Nitroglycerin LingualSpray400 ug/1OralREMEDYREPACK INC.2018-03-012020-05-11US flag
Nitroglycerin LingualSpray400 ug/1OralNucare Pharmaceuticals,inc.2013-09-20Not applicableUS flag
Nitroglycerin Transdermal Delivery SystemPatch10 mg/1dTransdermalPhysicians Total Care, Inc.2004-10-27Not applicableUS flag
Nitroglycerin Transdermal Delivery SystemPatch0.4 mg/1hTransdermalAlvogen, Inc.2010-11-102021-10-01US flag
Nitroglycerin Transdermal Delivery SystemPatch5 mg/1dTransdermalGraceway Pharmaceuticals2007-04-01Not applicableUS flag
Nitroglycerin Transdermal Delivery SystemPatch0.2 mg/1hTransdermalAlvogen, Inc.2010-11-102021-08-01US flag
Nitroglycerin Transdermal Delivery SystemPatch5 mg/1dTransdermalPhysicians Total Care, Inc.2004-10-12Not applicableUS flag
Nitroglycerin Transdermal Delivery SystemPatch2.5 mg/1dTransdermalGraceway Pharmaceuticals2007-04-01Not applicableUS flag
Nitroglycerin Transdermal Delivery SystemPatch15 mg/1dTransdermalGraceway Pharmaceuticals2007-04-01Not applicableUS flag
Nitroglycerin Transdermal Delivery SystemPatch15 mg/1dTransdermalPhysicians Total Care, Inc.2007-04-012010-12-31US flag
Nitroglycerin Transdermal Delivery SystemPatch0.6 mg/1hTransdermalAlvogen, Inc.2010-11-102021-08-01US flag
Nitroglycerin Transdermal Delivery SystemPatch10 mg/1dTransdermalGraceway Pharmaceuticals2007-04-04Not applicableUS flag
Nitroglycerin Transdermal Delivery SystemPatch0.1 mg/1hTransdermalAlvogen, Inc.2010-11-102021-08-01US flag
Nitroglycerin Transdermal Delivery SystemPatch2.5 mg/1dTransdermalPhysicians Total Care, Inc.2006-05-30Not applicableUS flag
Nitroglycerin Transdermal Infusion SystemPatch80 mg/1TransdermalDr. Reddy's Laboratories, Inc.2020-03-01Not applicableUS flag
Nitroglycerin Transdermal Infusion SystemPatch40 mg/1TransdermalDr. Reddy's Laboratories, Inc.2020-03-01Not applicableUS flag
Nitroglycerin Transdermal Infusion SystemPatch120 mg/1TransdermalDr. Reddy's Laboratories, Inc.2020-03-01Not applicableUS flag
Nitroglycerin Transdermal Infusion SystemPatch20 mg/1TransdermalDr. Reddy's Laboratories, Inc.2020-03-01Not applicableUS flag
Nitroglycerin Transdermal SystemPatch, extended release0.4 mg/1hTransdermalZydus Pharmaceuticals USA Inc.2017-02-15Not applicableUS flag
Nitroglycerin Transdermal SystemPatch0.4 mg/1hTransdermalMajor Pharmaceuticals1998-10-30Not applicableUS flag
Nitroglycerin Transdermal SystemPatch0.6 mg/1hTransdermalHercon Laboratories Corporation1998-10-302019-12-31US flag
Nitroglycerin Transdermal SystemPatch0.2 mg/1hTransdermalCardinal Health1998-10-302012-03-31US flag
Nitroglycerin Transdermal SystemPatch, extended release0.2 mg/1hTransdermalZydus Pharmaceuticals USA Inc.2017-02-15Not applicableUS flag
Nitroglycerin Transdermal SystemPatch0.2 mg/1hTransdermalMajor Pharmaceuticals1998-10-30Not applicableUS flag
Nitroglycerin Transdermal SystemPatch, extended release0.1 mg/1hTransdermalZydus Pharmaceuticals USA Inc.2018-02-08Not applicableUS flag
Nitroglycerin Transdermal SystemPatch0.4 mg/1hTransdermalHercon Laboratories Corporation1998-10-302019-09-30US flag
Nitroglycerin Transdermal SystemPatch, extended release0.6 mg/1hTransdermalZydus Pharmaceuticals USA Inc.2017-02-15Not applicableUS flag
Nitroglycerin Transdermal SystemPatch0.6 mg/1hTransdermalMajor Pharmaceuticals1998-10-30Not applicableUS flag
Nitroglycerin Transdermal SystemPatch0.2 mg/1hTransdermalHercon Laboratories Corporation1998-10-302019-09-30US flag
Rho-nitro PumpspraySpray, metered0.4 mg / actSublingualSandoz Canada Incorporated2001-12-20Not applicableCanada flag
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
ANGISED TABLET 0.5 mgTablet0.5 mgOralGLAXOSMITHKLINE PTE LTD1988-06-24Not applicableSingapore flag
GLYTRIN SPRAYSpray400 mcg/spraySubmucosalJOYSON PTE. LTD.1997-01-21Not applicableSingapore flag
MYONIT INSTA NITROGLYCERIN SUBLINGUAL TABLETS USP 0.5MGTablet0.5 mgSublingualTRINITY PHARMACEUTICALS & FOOD PTE. LTD.2019-05-31Not applicableSingapore flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
NITROGLICERINA 0.1 MG/ML EN DEXTROSA 5% SOLUCION INYECTABLENitroglycerin (21.05 mg) + D-glucose monohydrate (8.518 g)SolutionIntravenousADS PHARMA S.A.S.2015-07-08Not applicableColombia flag
Nitroglycerin In 5% Dextrose Inj.-100mcg/mlNitroglycerin (10 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL)SolutionIntravenousBaxter Laboratories1995-12-312016-02-26Canada flag
Nitroglycerin In 5% Dextrose Inj.-200mcg/mlNitroglycerin (20 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL)SolutionIntravenousBaxter Laboratories1995-12-31Not applicableCanada flag
Nitroglycerin In 5% Dextrose Inj.-400mcg/mlNitroglycerin (40 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL)SolutionIntravenousBaxter Laboratories1995-12-31Not applicableCanada flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Basic Dental Emergency KitNitroglycerin (0.4 mg/1) + Acetylsalicylic acid (325 mg/1) + Albuterol sulfate (108 ug/1) + D-glucose (4000 mg/1) + Diphenhydramine hydrochloride (50 mg/1mL) + Epinephrine (0.3 mg/0.3mL)Aerosol, metered; Injection; Kit; Tablet; Tablet, chewableIntramuscular; Intravenous; Oral; Respiratory (inhalation); Subcutaneous; SublingualBest Dental Kit LLC2023-01-30Not applicableUS flag
Deluxe Dental Emergency KitNitroglycerin (0.4 mg/1) + Acetylsalicylic acid (325 mg/1) + Albuterol sulfate (108 ug/1) + D-glucose (4000 mg/1) + Diphenhydramine hydrochloride (50 mg/1mL) + Diphenhydramine hydrochloride (12.5 mg/5mL) + Epinephrine (0.3 mg/0.3mL) + Epinephrine (0.15 mg/0.15mL)Aerosol, metered; Injection; Kit; Solution; Tablet; Tablet, chewableIntramuscular; Intravenous; Oral; Respiratory (inhalation); Subcutaneous; SublingualBest Dental Kit LLC2023-01-30Not applicableUS flag
Nitro-TimeNitroglycerin (6.5 mg/1)CapsuleOralMajor Pharmaceuticals2004-01-292022-02-28US flag
Nitro-TimeNitroglycerin (6.5 mg/1)CapsuleOralCarilion Materials Management2004-01-29Not applicableUS flag
Nitro-timeNitroglycerin (2.5 mg/1)CapsuleOralTIME CAP LABORATORIES, INC2014-06-19Not applicableUS flag
Nitro-TimeNitroglycerin (6.5 mg/1)CapsuleOralAvera McKennan Hospital2015-04-242017-05-24US flag
Nitro-timeNitroglycerin (9 mg/1)CapsuleOralTIME CAP LABORATORIES, INC2014-06-19Not applicableUS flag
Nitro-TimeNitroglycerin (2.5 mg/1)CapsuleOralMajor Pharmaceuticals2004-01-292022-10-31US flag
Nitro-TimeNitroglycerin (2.5 mg/1)CapsuleOralCarilion Materials Management2004-01-29Not applicableUS flag
Nitro-TimeNitroglycerin (9.0 mg/1)CapsuleOralMajor Pharmaceuticals2004-01-292022-12-31US flag
Nitro-timeNitroglycerin (6.5 mg/1)CapsuleOralTIME CAP LABORATORIES, INC2014-06-19Not applicableUS flag
NitroglycerinNitroglycerin (9 mg/1)CapsuleOralPD-Rx Pharmaceuticals, Inc.2014-06-19Not applicableUS flag
NitroglycerinNitroglycerin (0.4 mg/1)TabletOralPreferred Pharmaceuticals, Inc2005-03-032019-01-25US flag
NitroglycerinNitroglycerin (0.3 mg/1)TabletOralGlenmark Generics, Inc. USA2005-03-032010-09-01US flag
NitroglycerinNitroglycerin (6.5 mg/1)CapsuleOralPD-Rx Pharmaceuticals, Inc.2014-06-19Not applicableUS flag
NitroglycerinNitroglycerin (9.0 mg/1)CapsuleOralCarilion Materials Management2004-01-29Not applicableUS flag
NitroglycerinNitroglycerin (0.4 mg/1)TabletOralRebel Distributors2005-03-03Not applicableUS flag
NitroglycerinNitroglycerin (0.6 mg/1)TabletOralGlenmark Generics, Inc. USA2005-03-032010-09-01US flag
NitroglycerinNitroglycerin (2.5 mg/1)CapsuleOralPD-Rx Pharmaceuticals, Inc.2014-06-19Not applicableUS flag
NitroglycerinNitroglycerin (0.4 mg/1)TabletOralGlenmark Generics, Inc. USA2005-03-032010-09-01US flag
Nitroglycerin ERNitroglycerin (2.5 mg/1)CapsuleOralAvKARE2012-12-19Not applicableUS flag
Nitroglycerin ERNitroglycerin (2.5 mg/1)CapsuleOralPD-Rx Pharmaceuticals, Inc.2014-06-20Not applicableUS flag
Nitroglycerin ERNitroglycerin (6.5 mg/1)CapsuleOralAvKARE2012-12-192021-01-31US flag
Nitroglycerin ERNitroglycerin (6.5 mg/1)CapsuleOralPD-Rx Pharmaceuticals, Inc.2010-05-10Not applicableUS flag
Nitroglycerin ERNitroglycerin (9 mg/1)CapsuleOralPD-Rx Pharmaceuticals, Inc.2010-05-10Not applicableUS flag
Nitroglycerin SlocapsNitroglycerin (2.5 mg/1)CapsuleOralRebel Distributors1982-08-25Not applicableUS flag
Nitroglycerin SlocapsNitroglycerin (6.5 mg/1)CapsuleOralEon Labs, Inc.1982-08-252011-05-31US flag
Nitroglycerin SlocapsNitroglycerin (2.5 mg/1)CapsuleOralEon Labs, Inc.1982-08-252011-05-31US flag
Nitroglycerin SlocapsNitroglycerin (9 mg/1)CapsuleOralEon Labs, Inc.1984-06-202011-05-31US flag
Nitroglycerin SlocapsNitroglycerin (6.5 mg/1)CapsuleOralRebel Distributors1982-08-25Not applicableUS flag
Nitroglycerin SRNitroglycerin (6.5 mg/1)CapsuleOralPhysicians Total Care, Inc.1995-12-202011-06-30US flag
NitronalNitroglycerin (1 mg/1mL)Injection, solutionIntravenousG. POHL-BOSKAMP GmbH & Co. KG2014-04-072016-03-22US flag

Categories

ATC Codes
C01DA02 — Glyceryl trinitrateC01DA52 — Glyceryl trinitrate, combinationsC05AE01 — Glyceryl trinitrate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alkyl nitrates. These are organic compounds containing a nitrate that is O-linked to an alkyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organic oxoanionic compounds
Sub Class
Organic nitrates
Direct Parent
Alkyl nitrates
Alternative Parents
Organic nitro compounds / Organic nitric acids and derivatives / Organooxygen compounds / Organic oxides / Organic nitrogen compounds / Hydrocarbon derivatives
Substituents
Aliphatic acyclic compound / Alkyl nitrate / Allyl-type 1,3-dipolar organic compound / Hydrocarbon derivative / Organic 1,3-dipolar compound / Organic nitric acid or derivatives / Organic nitro compound / Organic nitrogen compound / Organic oxide / Organooxygen compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
nitroglycerol (CHEBI:28787) / a small molecule (CPD-143)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
G59M7S0WS3
CAS number
55-63-0
InChI Key
SNIOPGDIGTZGOP-UHFFFAOYSA-N
InChI
InChI=1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2
IUPAC Name
1,3-bis(nitrooxy)propan-2-yl nitrate
SMILES
[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O

References

Synthesis Reference

Izhak Blank, "Nitroglycerin preparations." U.S. Patent US4482534, issued December, 1979.

US4482534
General References
  1. Ignarro LJ: After 130 years, the molecular mechanism of action of nitroglycerin is revealed. Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7816-7. doi: 10.1073/pnas.132271799. [Article]
  2. Chen Z, Zhang J, Stamler JS: Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8306-11. doi: 10.1073/pnas.122225199. Epub 2002 Jun 4. [Article]
  3. Ferreira JC, Mochly-Rosen D: Nitroglycerin use in myocardial infarction patients. Circ J. 2012;76(1):15-21. Epub 2011 Nov 1. [Article]
  4. Blagodatskikh SV, Piotrovskii VK, Metelits VI, Riabokon' OS, Martsevich SIu: [Pharmacokinetics of glycerin trinitrate (nitroglycerin) after sublingual administration in patients with chronic ischemic heart disease]. Farmakol Toksikol. 1987 Nov-Dec;50(6):59-63. [Article]
  5. McNiff EF, Yacobi A, Young-Chang FM, Golden LH, Goldfarb A, Fung HL: Nitroglycerin pharmacokinetics after intravenous infusion in normal subjects. J Pharm Sci. 1981 Sep;70(9):1054-8. [Article]
  6. Cossum PA, Roberts MS, Yong AC, Kilpatrick D: Distribution and metabolism of nitroglycerin and its metabolites in vascular beds of sheep. J Pharmacol Exp Ther. 1986 Jun;237(3):959-66. [Article]
  7. Madhani M, Scotland RS, MacAllister RJ, Hobbs AJ: Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling. Br J Pharmacol. 2003 Aug;139(7):1289-96. [Article]
  8. Chen Z, Stamler JS: Bioactivation of nitroglycerin by the mitochondrial aldehyde dehydrogenase. Trends Cardiovasc Med. 2006 Nov;16(8):259-65. doi: 10.1016/j.tcm.2006.05.001. [Article]
  9. Marsh N, Marsh A: A short history of nitroglycerine and nitric oxide in pharmacology and physiology. Clin Exp Pharmacol Physiol. 2000 Apr;27(4):313-9. doi: 10.1046/j.1440-1681.2000.03240.x. [Article]
  10. Kim KH, Kerndt CC, Adnan G, Schaller DJ: Nitroglycerin . [Article]
  11. FDA Approved Drug Products: Nitroglycerin in 5% Dextrose Injection, for intravenous use [Link]
  12. Health Canada Approved Drug Products: NITROLINGUAL PUMPSPRAY (Nitroglycerin) Sublingual Spray [Link]
  13. Pfizer: Nitroglycerin MSDS [Link]
  14. FDA Approved Drug Products: NITRO-DUR (nitroglycerin) Transdermal Infusion System [Link]
  15. FDA Approved Drug Products: NitroMist (nitroglycerin) lingual aerosol [Link]
  16. DailyMed Label: RECTIV (nitroglycerin) Ointment 0.4%, for intra-anal use [Link]
  17. DailyMed Label: NITROSTAT (nitroglycerin) sublingual tablet [Link]
Human Metabolome Database
HMDB0014865
KEGG Drug
D00515
KEGG Compound
C07455
PubChem Compound
4510
PubChem Substance
46509120
ChemSpider
4354
RxNav
4917
ChEBI
28787
ChEMBL
CHEMBL730
ZINC
ZINC000008214625
Therapeutic Targets Database
DNC001024
PharmGKB
PA450644
PDBe Ligand
TNG
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Nitroglycerin
PDB Entries
4fr8

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedDiagnosticCoronary Artery Disease (CAD)1
4CompletedOtherCardiopulmonary Bypass / Coronary Artery Bypass Grafting (CABG)1
4CompletedPreventionAnginal Pain / Coronary Artery Disease (CAD) / Radial Artery Spasm1
4CompletedPreventionProphylaxis of Contrast-induced nephropathy1
4CompletedSupportive CareDeliberate Hypotension / Sinus Endoscopic Surgery / Tissue Perfusion1
4CompletedSupportive CareManaging Preterm Labor1
4CompletedTreatmentAcute Decompensated Heart Failure (ADHF)1
4CompletedTreatmentAcute Heart Failure (AHF)1
4CompletedTreatmentAcute Myocardial Infarction (AMI) / Percutaneous Coronary Intervention (PCI)1
4CompletedTreatmentAngina Pectoris1
4CompletedTreatmentCardiovascular Disease (CVD) / Chronic Kidney Disease (CKD)1
4CompletedTreatmentChronic Anal Fissures / Fissure;Anal1
4CompletedTreatmentCoronary Slow Flow Phenomenon / ST Segment Elevation Myocardial Infarction (STEMI)1
4CompletedTreatmentEndotoxin, Escherichia Coli / Regional Blood Flow / Retina1
4CompletedTreatmentEsophageal Food Bolus Obstruction1
4CompletedTreatmentHeart Transplantation / Hypertension1
4CompletedTreatmentIUD Insertion1
4CompletedTreatmentKidney Failure1
4CompletedTreatmentLabor; Prolonged, Second Stage1
4CompletedTreatmentNormal, or Near Normal Coronary Angiography / Slow Coronary Flow / Stable Angina (SA)1
4CompletedTreatmentPlacenta, Retained2
4Not Yet RecruitingPreventionPre-eclampsia Aggravated / Pre-Eclampsia; Complicating Pregnancy1
4Not Yet RecruitingTreatmentChinese Herbal Medicine / Coronary Heart Disease (CHD) / Unstable Angina Pectoris1
4RecruitingHealth Services ResearchCerebral Vasospasm1
4RecruitingTreatmentGender Dysphoria1
4Unknown StatusPreventionRadial Artery Injury1
4Unknown StatusSupportive CareCoronary Artery Disease (CAD)1
4Unknown StatusTreatmentAngina Pectoris1
4Unknown StatusTreatmentContraception1
4Unknown StatusTreatmentCoronary Heart Disease (CHD) / Stable Angina (SA)2
4Unknown StatusTreatmentMicrocirculation / Severe Sepsis1
4Unknown StatusTreatmentST Segment Elevation Myocardial Infarction (STEMI)1
4Unknown StatusTreatmentStable Angina (SA)1
4WithdrawnTreatmentFissure;Anal1
3CompletedPreventionCardiac Catheterisation1
3CompletedPreventionOcclusion of Artery / Radial Artery Injury at Wrist and Hand Level / Vasodilation1
3CompletedPreventionOsteopenia (Disorder) / Osteoporosis1
3CompletedPreventionOsteoporosis1
3CompletedTreatmentAutoimmune Disorder / Raynaud's Phenomenon / Scleroderma1
3CompletedTreatmentCardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Myocardial Infarction / Myocardial Ischemia1
3CompletedTreatmentChronic Anal Fissures1
3CompletedTreatmentErectile Dysfunction1
3CompletedTreatmentFissure in Ano1
3CompletedTreatmentFissure in Ano / Pain1
3CompletedTreatmentHeart Failure / Hypertension1
3CompletedTreatmentHypertension1
3CompletedTreatmentInternal Mammary Artery Syndrome / Vasodilation1
3CompletedTreatmentOsteoporosis1
3CompletedTreatmentPain2
3CompletedTreatmentRaynaud's Phenomenon1
3CompletedTreatmentReperfusion Injury, Myocardial1
3CompletedTreatmentRheumatoid Arthritis1
3CompletedTreatmentSepsis / Septic Shock1
3RecruitingPreventionRadial Artery Spasm1
3Unknown StatusPreventionInjury of Radial Artery1
3Unknown StatusPreventionTotal Atherosclerotic Occlusion of Radial Artery1
3Unknown StatusTreatmentRaynaud's Disease Secondary to Other Autoimmune Disease / Raynaud's Disease Secondary to Scleroderma / Raynaud's Phenomenon1
3Unknown StatusTreatmentRaynaud's Phenomenon1
3Unknown StatusTreatmentStroke1
3WithdrawnTreatmentGynecomastia / Impaired Wound Healing1
2CompletedTreatmentCardiac Failure / Heart Failure / Reduced Ventricular Ejection Fraction1
2CompletedTreatmentCerebral Oxygenation1
2CompletedTreatmentChest Pain / Sickle Cell Anemia1
2CompletedTreatmentCoronary Artery Disease (CAD)1
2CompletedTreatmentDiabetic Peripheral Neuropathy (DPN)1
2CompletedTreatmentDigital Ulcer of Scleroderma1
2CompletedTreatmentErectile Dysfunction1
2CompletedTreatmentMenopause-Related Hot Flashes1
2CompletedTreatmentNon-Small Cell Lung Cancer (NSCLC)1
2CompletedTreatmentRaynaud's Phenomenon1
2CompletedTreatmentRaynaud's Phenomenon Secondary to Connective Tissue Disease1
2CompletedTreatmentStroke, Acute1
2CompletedTreatmentVasospastic Angina1
2Not Yet RecruitingSupportive CareAutonomic Dysreflexia / Spinal Cord Injuries1
2TerminatedTreatmentCerebral Hemorrhage / Ischemic Stroke1
2TerminatedTreatmentNon-Small Cell Lung Cancer (NSCLC)1
2Unknown StatusTreatmentColic / Functional disorders of the biliary tract1
2Unknown StatusTreatmentCoronary Heart Disease (CHD)1
2Unknown StatusTreatmentLocally Advanced Non-Small Cell Lung Cancer1
2Unknown StatusTreatmentLung Cancer1
2Unknown StatusTreatmentShock, Hemorrhagic1
2Unknown StatusTreatmentTendonitis1
2, 3CompletedPreventionRaynaud's Disease Secondary to Other Autoimmune Disease / Raynaud's Disease Secondary to Scleroderma / Raynaud's Phenomenon1
2, 3CompletedTreatmentCardiac Catheterizations / Spasms1
2, 3CompletedTreatmentHeart Failure1
2, 3CompletedTreatmentInduction of Labor Affected Fetus / Newborn1
2, 3CompletedTreatmentPain After Stapled Haemorrhoidopexy1
2, 3Enrolling by InvitationTreatmentPulmonary Edemas1
2, 3TerminatedPreventionERCP / Pancreatitis1
2, 3TerminatedPreventionPerfusion; Complications1
2, 3TerminatedTreatmentExternal Cephalic Version1
1Active Not RecruitingOtherHypertension1
1CompletedNot AvailableInflammation1
1CompletedDiagnosticErectile Dysfunction1
1CompletedOtherHealthy Volunteers (HV)1
1CompletedTreatmentCoronary Artery Disease (CAD)1
1CompletedTreatmentErectile Dysfunction1
1CompletedTreatmentHealthy Volunteers (HV)1
1CompletedTreatmentHypertension1
1CompletedTreatmentRaynaud's Phenomenon2
1CompletedTreatmentRectal Cancer1
1Unknown StatusTreatmentPulmonary Hypertension (PH)1
1, 2CompletedBasic ScienceMicrovascular Dysfunction1
1, 2CompletedPreventionCatheter Related Infections / Catheter-Associated Infections1
1, 2RecruitingOtherFunctional Endoscopic Sinus Surgery (FESS)1
1, 2TerminatedOtherHypotensive Anesthesia1
1, 2Unknown StatusPreventionPhlebitis1
0CompletedBasic ScienceRadial Artery Injury Prevetion1
0CompletedScreeningColonic Adenomatous Polyps / Colorectal Cancer / Colorectal Neoplasms1
0CompletedSupportive CareControlled Hypotension for Nasal Surgeries1
0Not Yet RecruitingOtherArtery; Dilatation1
0RecruitingBasic ScienceAdipose Tissue, Brown1
0RecruitingDiagnosticObstructive Sleep Apnea (OSA)1
0Unknown StatusDiagnosticEffect of Drugs1
0Unknown StatusTreatmentPeripheral Arterial Disease (PAD)1
Not AvailableActive Not RecruitingTreatmentCardiovascular Disease (CVD)1
Not AvailableCompletedNot AvailableCardiovascular Shock / Circulatory collapse and shock1
Not AvailableCompletedNot AvailableCognitive Dysfunctions / Hypotension; Controlled1
Not AvailableCompletedNot AvailableHypertension1
Not AvailableCompletedBasic ScienceBrain Disorders / Central Nervous System Disorder / Diseases of the Nervous System / Headache Disorders / Headache Disorders, Primary / Migraine / Migraine Without Aura1
Not AvailableCompletedBasic ScienceFamilial Hemiplegic Migraine1
Not AvailableCompletedBasic ScienceGlaucoma1
Not AvailableCompletedBasic ScienceNitric Oxide / Oral Soft Tissue Conditions / Vasodilation1
Not AvailableCompletedBasic ScienceOral Soft Tissue Conditions / Vasodilation1
Not AvailableCompletedBasic SciencePsychosis / Schizophrenia1
Not AvailableCompletedBasic ScienceRetinal Hypoxia1
Not AvailableCompletedPreventionAcute Kidney Injury (AKI)1
Not AvailableCompletedPreventionContraception / Pain1
Not AvailableCompletedPreventionEsophageal Neoplasms / Microcirculation1
Not AvailableCompletedPreventionInjury of Radial Artery1
Not AvailableCompletedTreatmentAchilles Tendon Pain (Achillodynia) / Tendinopathy1
Not AvailableCompletedTreatmentAnesthesia therapy / Hypotension1
Not AvailableCompletedTreatmentArterial Lines1
Not AvailableCompletedTreatmentBreech Presentation / Complication of Pregnancy1
Not AvailableCompletedTreatmentBreech Presentation / Pregnancy, Complications1
Not AvailableCompletedTreatmentCerebral Hemorrhage / Intracranial Hemorrhages / Stroke1
Not AvailableCompletedTreatmentCoronaropathy1
Not AvailableCompletedTreatmentCoronavirus Disease 2019 (COVID‑19) / Infections, Coronavirus1
Not AvailableCompletedTreatmentFemale Infertility / Polycystic Ovarian Syndrome (PCOS)1
Not AvailableCompletedTreatmentFissure;Anal1
Not AvailableCompletedTreatmentHyperglycemia / Lactic Acidosis1
Not AvailableCompletedTreatmentHypertension1
Not AvailableCompletedTreatmentHypertensive Anal Canal1
Not AvailableCompletedTreatmentMastectomy Flap Necrosis1
Not AvailableCompletedTreatmentPostpartum Haemorrhage (PPH)1
Not AvailableCompletedTreatmentPre-Eclampsia, Severe1
Not AvailableCompletedTreatmentTrigger Points, Myofascial1
Not AvailableEnrolling by InvitationNot AvailableHemorrhage / Malocclusion / Maxillofacial Injuries / Orthodontics1
Not AvailableNot Yet RecruitingPreventionExternal Dacryocystorhinostomy Operation / Patient With Nasolacrimal Duct Obstruction1
Not AvailableNot Yet RecruitingPreventionHemodynamics Instability / Hepatectomy / Sildenafil / Venous Pressure, Central1
Not AvailableNot Yet RecruitingTreatmentPre-Eclampsia, Severe1
Not AvailableRecruitingNot AvailableAcute Kidney Injury (Nontraumatic) / Hypotension Drug-Induced1
Not AvailableRecruitingNot AvailableAortic Stenosis / Hypertension, Essential Hypertension / Impaired Renal Function / Secondary Hypertension1
Not AvailableRecruitingNot AvailableMigraine1
Not AvailableRecruitingNot AvailableNon Obstructive Coronary Atherosclerosis1
Not AvailableRecruitingBasic ScienceMigraine / Pain1
Not AvailableRecruitingPreventionArterial Lines / Ischaemia1
Not AvailableRecruitingTreatmentBrain Metastases / EGFR Gene Mutations / Non-Small Cell Lung Cancer (NSCLC)1
Not AvailableRecruitingTreatmentEchocardiography / Pulmonary Hypertension, Persistent, of the Newborn / Respiratory Diseases1
Not AvailableRecruitingTreatmentRetinoblastoma1
Not AvailableTerminatedOtherEnd Stage Renal Disease (ESRD)1
Not AvailableTerminatedTreatmentChronic Kidney Disease (CKD)1
Not AvailableUnknown StatusNot AvailableCoronary Ischemia1
Not AvailableUnknown StatusEducational/Counseling/TrainingHealthy Volunteers (HV)1
Not AvailableUnknown StatusTreatmentHypotension; Controlled1
Not AvailableWithdrawnNot AvailableCoronary Heart Disease (CHD)1
Not AvailableWithdrawnHealth Services ResearchHealthy Volunteers (HV)1

Pharmacoeconomics

Manufacturers
  • Novadel pharma inc
  • Pohl boskamp
  • Graceway pharmaceuticals llc
  • Key pharmaceuticals inc sub schering plough corp
  • Hercon laboratories corp
  • Kremers urban co
  • Mylan technologies inc
  • Novartis pharmaceuticals corp
  • G pohl boskamp gmbh and co
  • Sanofi aventis us llc
  • Abraxis pharmaceutical products
  • Hospira inc
  • International medication systems ltd
  • Luitpold pharmaceuticals inc
  • Smith and nephew solopak div smith and nephew
  • Baxter healthcare corp
  • Rorer pharmaceutical corp sub rorer group
  • Parke davis div warner lambert co
  • E fougera div altana inc
  • Pfizer pharmaceuticals ltd
Packagers
  • 3M Health Care
  • Akrimax Pharmaceuticals
  • American Regent
  • A-S Medication Solutions LLC
  • Baxter International Inc.
  • Bradley Pharmaceuticals Inc.
  • Bristol-Myers Squibb Co.
  • C.O. Truxton Inc.
  • Cardinal Health
  • Concord Labs
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • E. Fougera and Co.
  • Eon Labs
  • Ethex Corp.
  • G Pohl Boskamp GmbH and Co. KG
  • Glenmark Generics Ltd.
  • Glenmark Pharmaceuticals
  • Graceway Pharmaceuticals
  • H and H Laboratories
  • Heartland Repack Services LLC
  • Hercon Laboratories Corp.
  • Hospira Inc.
  • Ivax Pharmaceuticals
  • Konec Inc.
  • Lake Erie Medical and Surgical Supply
  • Lohmann Tiererahrung GmbH
  • LTS Lohmann Therapy Systems Corp.
  • Luitpold Pharmaceuticals Inc.
  • Major Pharmaceuticals
  • Mckesson Corp.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Neuman Distributors Inc.
  • Nippon Kayaku Co. Ltd.
  • North Safety Products
  • Novartis AG
  • Nubenco Enterprises Inc.
  • Nycomed Inc.
  • Pfizer Inc.
  • Pharmedix
  • Physician Partners Ltd.
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prepak Systems Inc.
  • Qualitest
  • Rebel Distributors Corp.
  • Redpharm Drug
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Sanofi-Aventis Inc.
  • Savage Labs
  • Schering Corp.
  • Schwarz Pharma Inc.
  • Sciele Pharma Inc.
  • Shire Inc.
  • Southwood Pharmaceuticals
  • Summit Pharmaceuticals
  • Time-Cap Labs
  • TriMarc Labs
  • United Research Laboratories Inc.
  • Valsynthese Ltd.
  • Vangard Labs Inc.
  • Vision Pharma LLC
Dosage Forms
FormRouteStrength
PatchTransdermal10 MG
PatchTransdermal15 MG
PatchTransdermal5 MG
SolutionIntravenous1.000 mg
TabletOral0.5 mg
OintmentRectal0.4 %
Aerosol, metered; injection; kit; tablet; tablet, chewableIntramuscular; Intravenous; Oral; Respiratory (inhalation); Subcutaneous; Sublingual
SolutionIntravenous50.000 mg
PatchTransdermal18.700 mg
Aerosol, metered; injection; kit; solution; tablet; tablet, chewableIntramuscular; Intravenous; Oral; Respiratory (inhalation); Subcutaneous; Sublingual
SolutionIntravenous25 mg
PatchTransdermal15 MG/24H
InjectionIntravenous
InjectionIntravenous50 mg/10ml
InjectionParenteral1 mg/ml
Injection, solutionIntravenous1 mg/ml
SolutionIntravenous1.000 MG/ML
InjectionIntravenous1 mg/1ml
Spray0.4 mg
SpraySubmucosal400 mcg/spray
SolutionSublingual400 mcg
PowderSublingual400 ug/1
TabletOral500 mcg
PatchTransdermal0.4 mg / hour
PatchTransdermal0.6 mg / hour
PatchTransdermal18 mg/1
PatchTransdermal18 mg/1[USP'U]
PatchTransdermal18000 ug/1
PatchTransdermal36 mg/1
PatchTransdermal36.000 mg
PatchTransdermal36000 ug/1
PatchTransdermal54 mg/1
PatchTransdermal54000 ug/1
PatchTransdermal9 mg/1
PatchTransdermal9000 ug/1
PatchTransdermal72 mg / 26.6 sq cm
PlasterCutaneous36 mg
Aerosol, meteredSublingual0.4 mg / act
TabletSublingual0.5 mg
SpraySublingual
TabletSublingual
SolutionIntravenous1 mg/ml
OintmentTopical20 mg/1g
PatchTransdermal
PatchTransdermal120 mg/1
PatchTransdermal160 mg/1
PatchTransdermal2.5 MG/DIE
PatchTransdermal20 mg/1
PatchTransdermal40 mg/1
PatchTransdermal60 mg/1
PatchTransdermal80 mg/1
Patch, extended releaseTransdermal0.2 mg / hour
Patch, extended releaseTransdermal60 mg / 15 sq cm
Patch, extended releaseTransdermal0.6 mg / hour
Patch, extended releaseTransdermal0.8 mg / hour
PatchTransdermal10 MG/24ORE
PatchTransdermal15 MG/24ORE
PatchTransdermal5 MG/24ORE
Ointment
PatchTransdermal25.000 mg
Patch, extended releaseTransdermal10 mg/24hr
PlasterCutaneous10 mg
Patch, extended releaseTransdermal10 mg/24h
PatchTransdermal50 mg
Patch, extended releaseTransdermal5 mg/24hr
PlasterCutaneous5 mg
Patch, extended releaseTransdermal5 mg/24h
PatchTransdermal25 mg
Tablet, extended releaseBuccal1 mg
SolutionParenteral5 mg
SolutionIntravenous50 mg
SolutionParenteral50 mg
SolutionIntravenous20 mg
SolutionIntravenous2000000 mg
Injection, solutionIntravenous
Injection, solution, concentrateIntravenous
Aerosol, meteredSublingual400 ug/1
CapsuleOral9.0 mg/1
Film, extended releaseTransdermal20.8 mg/1
Film, extended releaseTransdermal37.4 mg/1
Injection, solutionIntravenous5 mg/1mL
Injection, solution, concentrateIntravenous5 mg/1mL
PatchTransdermal0.1 mg/1h
PatchTransdermal0.4 mg/1h
PatchTransdermal0.6 mg/1h
TabletOral0.4 mg/1
TabletSublingual0.3 mg/1
TabletSublingual0.6 mg/1
Tablet, orally disintegratingSublingual0.3 mg/1
Tablet, orally disintegratingSublingual0.4 mg/1
Tablet, orally disintegratingSublingual0.6 mg/1
SolutionIntravenous
InjectionIntravenous10 mg/100mL
InjectionIntravenous20 mg/100mL
InjectionIntravenous40 mg/100mL
Injection, solutionIntravenous100 ug/1mL
Injection, solutionIntravenous200 ug/1mL
Injection, solutionIntravenous400 ug/1mL
LiquidIntravenous5 mg / mL
CapsuleOral2.5 mg/1
CapsuleOral6.5 mg/1
CapsuleOral9 mg/1
PatchTransdermal10 mg/1d
PatchTransdermal15 mg/1d
PatchTransdermal2.5 mg/1d
PatchTransdermal5 mg/1d
PatchTransdermal0.2 mg/1h
Patch, extended releaseTransdermal0.1 mg/1h
Patch, extended releaseTransdermal0.2 mg/1h
Patch, extended releaseTransdermal0.4 mg/1h
Patch, extended releaseTransdermal0.6 mg/1h
SolutionIntravenous50 mg / 10 mL
SolutionIntravenous10 mg / 10 mL
Capsule, extended releaseOral
OintmentTopical2 %
SprayOral400 ug/1
Spray, meteredSublingual400 ug/1
SprayOral0.4 mg
SprayOral0.41 mg
SpraySublingual0.4 mg
Spray, meteredOral400 ug/1
Spray, meteredSublingual0.4 mg / act
Aerosol, sprayTransmucosal400 ug/1
Injection, solutionIntravenous1 mg/1mL
Tablet, extended releaseOral2.6 mg
Aerosol, spraySublingual
TabletOral0.3 mg/1
TabletOral0.6 mg/1
TabletSublingual0.3 mg
TabletSublingual0.4 mg/1
TabletSublingual0.6 mg
InjectionParenteral10 mg/10ml
OintmentRectal4 mg/1g
OintmentRectal
OintmentRectal4 mg/g
OintmentTopical0.2 % w/w
OintmentRectal0.2 %
Patch, extended releaseTransdermal12.5 mg/1
Patch, extended releaseTransdermal25 mg/1
Patch, extended releaseTransdermal50 mg/1
Patch, extended releaseTransdermal75 mg/1
Patch, extended releaseTransdermal0.4 mg / hour
Patch, extended releaseTransdermal100 mg / srd
PatchTransdermal0.2 mg / hour
PatchTransdermal10 MG/24h
PatchTransdermal5 MG/24h
Patch, extended releaseTransdermal15 mg/24hr
Injection, solutionIntravenous5 MG/1.5ML
Injection, solutionIntravenous50 MG/50ML
Injection, solution, concentrateIntravenous; Parenteral5 MG/1.5ML
Injection, solution, concentrateIntravenous; Parenteral50 MG/50ML
Tablet, coated0.3 MG
Injection, solution, concentrateIntravenous5 mg
Injection, solution, concentrateIntravenous5 MG/1.5ML
Solution5 mg/1ml
Prices
Unit descriptionCostUnit
Nitrolingual 0.4 mg/spray Solution 12 gm Bottle242.83USD bottle
Nitrolingual 0.4 mg/spray Solution 4.9 gm Bottle141.43USD bottle
Nitro-Dur 30 0.6 mg/hr Patches Box130.86USD box
Nitro-Dur 30 0.8 mg/hr Patches Box130.86USD box
Nitro-Dur 30 0.3 mg/hr Patches Box120.68USD box
Nitro-Dur 30 0.4 mg/hr Patches Box117.1USD box
Minitran 30 0.6 mg/hr Patches Box114.01USD box
Nitro-Dur 30 0.1 mg/hr Patches Box106.09USD box
Nitro-Dur 30 0.2 mg/hr Patches Box105.6USD box
Minitran 30 0.4 mg/hr Patches Box105.18USD box
Minitran 30 0.2 mg/hr Patches Box93.86USD box
Minitran 30 0.1 mg/hr Patches Box92.36USD box
Nitroglycerin 30 0.6 mg/hr Patches Box63.55USD box
Nitroglycerin 5 mg/ml kit62.38USD kit
Nitroglycerin 30 0.4 mg/hr Patches Box57.62USD box
Nitroglycerin 30 0.2 mg/hr Patches Box50.44USD box
Nitrostat 100 0.4 mg Sublingual Tabs Bottle29.88USD bottle
Nitromist 400 mcg spray28.5USD g
Nitrostat 100 0.3 mg Sublingual Tabs Bottle27.75USD bottle
Nitrostat 100 0.6 mg Sublingual Tabs Bottle24.99USD bottle
Nitroglycerin 100 0.6 mg Sublingual Tabs Bottle23.99USD bottle
Nitroglycerin 100 0.3 mg Sublingual Tabs Bottle22.99USD bottle
Nitrostat 25 0.4 mg Sublingual Tabs Bottle19.31USD bottle
Nitroglycerin 25 0.4 mg Sublingual Tabs Bottle9.5USD bottle
Nitro-dur 0.6 mg/hr patch4.19USD patch
Nitro-dur 0.8 mg/hr patch4.19USD patch
Nitro-dur 0.3 mg/hr patch3.87USD patch
Nitro-dur 0.4 mg/hr patch3.87USD patch
Minitran 0.6 mg/hr patch3.51USD patch
Nitro-dur 0.2 mg/hr patch3.45USD patch
Nitro-dur 0.1 mg/hr patch3.4USD patch
Minitran 0.4 mg/hr patch3.24USD patch
Minitran 0.2 mg/hr patch2.89USD patch
Minitran 0.1 mg/hr patch2.84USD patch
Nitroglycerin CR 6.5 mg capsule1.66USD capsule
Nitroglycerin 0.1 mg/hr Patches1.64USD patch
Nitroglycerin CR 9 mg capsule1.27USD capsule
Nitro-Dur 0.8 0.8 mg/hr Patch1.16USD patch
Nitroglycerin er 9 mg capsule1.0USD capsule
Transderm-Nitro 0.4 0.4 mg/hr Patch0.81USD patch
Transderm-Nitro 0.6 0.6 mg/hr Patch0.81USD patch
Minitran 0.4 0.4 mg/hr Patch0.74USD patch
Minitran 0.6 0.6 mg/hr Patch0.74USD patch
Nitroglycerin er 6.5 mg capsule0.72USD capsule
Transderm-Nitro 0.2 0.2 mg/hr Patch0.71USD patch
Nitro-Dur 0.4 0.4 mg/hr Patch0.67USD patch
Nitro-Dur 0.6 0.6 mg/hr Patch0.67USD patch
Trinipatch 0.4 0.4 mg/hr Patch0.67USD patch
Trinipatch 0.6 0.6 mg/hr Patch0.67USD patch
Minitran 0.2 0.2 mg/hr Patch0.66USD patch
Nitrol 2 % Ointment0.64USD g
Nitro-Dur 0.2 0.2 mg/hr Patch0.59USD patch
Trinipatch 0.2 0.2 mg/hr Patch0.59USD patch
Nitroglycerin 9 mg capsule sa0.53USD capsule
Nitro-bid 2% ointment0.48USD g
Nitroglycerin CR 2.5 mg capsule0.47USD capsule
Nitro-time er 9 mg capsule0.37USD capsule
Nitroglycerin 0.4 mg tablet sl0.36USD tablet
Nitrostat 0.4 mg tablet sl0.35USD tablet
Nitro-time er 6.5 mg capsule0.33USD capsule
Nitro-time er 2.5 mg capsule0.29USD capsule
Nitroglycerin er 2.5 mg capsule0.28USD capsule
Nitroglycerin 6.5 mg capsule sa0.22USD capsule
Nitroquick 0.3 mg tablet sl0.19USD tablet
Nitroglycerin 2.5 mg capsule sa0.18USD capsule
Nitroglycerin 2% ointment0.17USD g
Nitrostat 0.6 mg tablet sl0.16USD tablet
Nitroglycerin 0.3 mg tablet sl0.14USD tablet
Nitroglycerin 0.6 mg tablet sl0.14USD tablet
Nitrostat 0.3 mg Sublingual Tablet0.13USD tablet
Nitrostat 0.6 mg Sublingual Tablet0.13USD tablet
Nitrolingual Pumpspray 0.4 mg/dose Metered Dose Spray0.08USD dose
Nitroquick 0.4 mg tablet sl0.08USD tablet
Nitroquick 0.6 mg tablet sl0.08USD tablet
Nitrostat 0.3 mg tablet sl0.07USD tablet
Mylan-Nitro 0.4 mg/dose Metered Dose Spray0.04USD dose
Ntg 25 mg/250 ml in d5w0.04USD ml
Rho-Nitro Pumpspray 0.4 mg/dose Metered Dose Spray0.04USD dose
Ntg 50 mg/500 ml in d5w0.02USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5186938No1993-02-162010-02-16US flag
US7872049No2011-01-182028-03-14US flag
US6500456No2002-12-312018-09-16US flag
US5869082No1999-02-092016-04-16US flag
US9101592No2015-08-112032-03-11US flag

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)13.5 http://www.inchem.org/documents/icsc/icsc/eics0186.htm
boiling point (°C)160http://www.inchem.org/documents/icsc/icsc/eics0186.htm
water solubilitypoor solubility in waterhttp://www.inchem.org/documents/icsc/icsc/eics0186.htm
logP1.62http://www.inchem.org/documents/icsc/icsc/eics0186.htm
logS-3http://www.hmdb.ca/metabolites/HMDB0014865
pKa-5.6http://www.hmdb.ca/metabolites/HMDB0014865
Predicted Properties
PropertyValueSource
Water Solubility0.204 mg/mLALOGPS
logP1.25ALOGPS
logP0.26Chemaxon
logS-3ALOGPS
pKa (Strongest Basic)-5.6Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count9Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area157.11 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity37.59 m3·mol-1Chemaxon
Polarizability15.68 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.7613
Blood Brain Barrier+0.9113
Caco-2 permeable-0.5775
P-glycoprotein substrateNon-substrate0.8322
P-glycoprotein inhibitor INon-inhibitor0.671
P-glycoprotein inhibitor IINon-inhibitor0.9005
Renal organic cation transporterNon-inhibitor0.8325
CYP450 2C9 substrateNon-substrate0.8982
CYP450 2D6 substrateNon-substrate0.9022
CYP450 3A4 substrateNon-substrate0.5255
CYP450 1A2 substrateNon-inhibitor0.8022
CYP450 2C9 inhibitorNon-inhibitor0.7789
CYP450 2D6 inhibitorNon-inhibitor0.9106
CYP450 2C19 inhibitorNon-inhibitor0.72
CYP450 3A4 inhibitorNon-inhibitor0.9173
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8638
Ames testAMES toxic0.9107
CarcinogenicityCarcinogens 0.6822
BiodegradationReady biodegradable0.9479
Rat acute toxicity2.9173 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.512
hERG inhibition (predictor II)Non-inhibitor0.9382
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.71 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0udi-2910000000-7e0a7efb140cbfba7482
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-147.0404626
predicted
DarkChem Lite v0.1.0
[M-H]-147.0637626
predicted
DarkChem Lite v0.1.0
[M-H]-120.897606
predicted
DeepCCS 1.0 (2019)
[M-H]-147.0404626
predicted
DarkChem Lite v0.1.0
[M-H]-147.0637626
predicted
DarkChem Lite v0.1.0
[M-H]-147.0404626
predicted
DarkChem Lite v0.1.0
[M-H]-147.0637626
predicted
DarkChem Lite v0.1.0
[M-H]-147.0404626
predicted
DarkChem Lite v0.1.0
[M-H]-147.0637626
predicted
DarkChem Lite v0.1.0
[M-H]-147.0404626
predicted
DarkChem Lite v0.1.0
[M-H]-147.0637626
predicted
DarkChem Lite v0.1.0
[M-H]-147.0404626
predicted
DarkChem Lite v0.1.0
[M-H]-147.0637626
predicted
DarkChem Lite v0.1.0
[M-H]-120.897606
predicted
DeepCCS 1.0 (2019)
[M-H]-120.897606
predicted
DeepCCS 1.0 (2019)
[M-H]-120.897606
predicted
DeepCCS 1.0 (2019)
[M-H]-120.897606
predicted
DeepCCS 1.0 (2019)
[M-H]-120.897606
predicted
DeepCCS 1.0 (2019)
[M+H]+146.3201626
predicted
DarkChem Lite v0.1.0
[M+H]+148.1231626
predicted
DarkChem Lite v0.1.0
[M+H]+123.7891
predicted
DeepCCS 1.0 (2019)
[M+H]+146.3201626
predicted
DarkChem Lite v0.1.0
[M+H]+148.1231626
predicted
DarkChem Lite v0.1.0
[M+H]+146.3201626
predicted
DarkChem Lite v0.1.0
[M+H]+148.1231626
predicted
DarkChem Lite v0.1.0
[M+H]+146.3201626
predicted
DarkChem Lite v0.1.0
[M+H]+148.1231626
predicted
DarkChem Lite v0.1.0
[M+H]+146.3201626
predicted
DarkChem Lite v0.1.0
[M+H]+148.1231626
predicted
DarkChem Lite v0.1.0
[M+H]+146.3201626
predicted
DarkChem Lite v0.1.0
[M+H]+148.1231626
predicted
DarkChem Lite v0.1.0
[M+H]+123.7891
predicted
DeepCCS 1.0 (2019)
[M+H]+123.7891
predicted
DeepCCS 1.0 (2019)
[M+H]+123.7891
predicted
DeepCCS 1.0 (2019)
[M+H]+123.7891
predicted
DeepCCS 1.0 (2019)
[M+H]+123.7891
predicted
DeepCCS 1.0 (2019)
[M+Na]+149.4105626
predicted
DarkChem Lite v0.1.0
[M+Na]+149.5838626
predicted
DarkChem Lite v0.1.0
[M+Na]+132.70872
predicted
DeepCCS 1.0 (2019)
[M+Na]+149.4105626
predicted
DarkChem Lite v0.1.0
[M+Na]+149.5838626
predicted
DarkChem Lite v0.1.0
[M+Na]+149.4105626
predicted
DarkChem Lite v0.1.0
[M+Na]+149.5838626
predicted
DarkChem Lite v0.1.0
[M+Na]+149.4105626
predicted
DarkChem Lite v0.1.0
[M+Na]+149.5838626
predicted
DarkChem Lite v0.1.0
[M+Na]+149.4105626
predicted
DarkChem Lite v0.1.0
[M+Na]+149.5838626
predicted
DarkChem Lite v0.1.0
[M+Na]+149.4105626
predicted
DarkChem Lite v0.1.0
[M+Na]+149.5838626
predicted
DarkChem Lite v0.1.0
[M+Na]+132.70872
predicted
DeepCCS 1.0 (2019)
[M+Na]+132.70872
predicted
DeepCCS 1.0 (2019)
[M+Na]+132.70872
predicted
DeepCCS 1.0 (2019)
[M+Na]+132.70872
predicted
DeepCCS 1.0 (2019)
[M+Na]+132.70872
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Atrial natriuretic peptide receptor 1
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Agonist
Curator comments
This is a possible target of nitroglycerin, supported by an in vitro study.
General Function
Protein kinase activity
Specific Function
Receptor for the atrial natriuretic peptide NPPA/ANP and the brain natriuretic peptide NPPB/BNP which are potent vasoactive hormones playing a key role in cardiovascular homeostasis. Has guanylate ...
Gene Name
NPR1
Uniprot ID
P16066
Uniprot Name
Atrial natriuretic peptide receptor 1
Molecular Weight
118918.11 Da
References
  1. Madhani M, Scotland RS, MacAllister RJ, Hobbs AJ: Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling. Br J Pharmacol. 2003 Aug;139(7):1289-96. [Article]

Enzymes

Details1. Aldehyde dehydrogenase, mitochondrial
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Electron carrier activity
Specific Function
Not Available
Gene Name
ALDH2
Uniprot ID
P05091
Uniprot Name
Aldehyde dehydrogenase, mitochondrial
Molecular Weight
56380.93 Da
References
  1. Badejo AM Jr, Hodnette C, Dhaliwal JS, Casey DB, Pankey E, Murthy SN, Nossaman BD, Hyman AL, Kadowitz PJ: Mitochondrial aldehyde dehydrogenase mediates vasodilator responses of glyceryl trinitrate and sodium nitrite in the pulmonary vascular bed of the rat. Am J Physiol Heart Circ Physiol. 2010 Sep;299(3):H819-26. doi: 10.1152/ajpheart.00959.2009. Epub 2010 Jun 11. [Article]
  2. Chen Z, Zhang J, Stamler JS: Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8306-11. doi: 10.1073/pnas.122225199. Epub 2002 Jun 4. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 05, 2024 03:44